annual reportkey figures group sales millions chf cer core operating profit millions chf cer core earnings per share chf cer operating free cash flow millions chf cer r investment millions chf cer dividend chf cer total shareholder return value chf invested period ending dec mar jun sep dec roche gs price roche b price peer set index patients clinical trials patients number employees employees cer constant exchange rates average fullyear proposed board directors prices translated constant chf exchange rates usd eur jpy gbp fulltime equivalents yado leinad nnamleggid dnalor key events roche group roche annual general management changes meeting shareholders daniel oday former head authorised dividend roche diagnostics increase chf per appointed new head share nonvoting equity roche pharma roland companys th diggelmann assumed dividend increase many position head years roche diagnostics roche continued streamline latestage pipeline research develop made considerable progress ment activities taking clini decision close site cal trials delivering positive nutley new jersey usa results underpinning respective r activities strength innovation consolidated strategy switzerland germany pharmaceuticals fda approved fda approved perjeta erivedge vismodegib pertuzumab patients firstinclass hedgehog herpositive meta pathway inhibitor static breast cancer new adults advanced personalised medicine gives basal cell carcinoma patients time without disease worsening new data phase iii second interim emilia study showed data analysis roches trastuzumab daloutcomes trial roche emtansine tdm decided discontinue significantly improved survival development dalcetrapib people herpositive medicine lower cardio metastatic breast cancer vascular risks roche filed approval fda emacorporate sustainability reduced second transnet water consumption phelophepa healthcare greenhouse gas train inaugurated emissions south africa roche doubled well track reach support reaching fiveyear goal people year improvement efficiency rural south africa trains various services roche recognised roche named great place work healthcare supersector achieving top rankings leader dow jones prestigious award listings sustainability indexes djsi worldwide fourth consecutive year ranking confir mation roches commit ment longterm sustainable value creation diagnostics new us guidelines recognise fda cleared benefit genotyping accuchek combo human papillomavirus system roches new inter hpv active insulin pump system principal causes cervical people diabetes cancer women accuchek nano smartview system roche applied science roche launched guideit diabetes care initiated clinical trial involving restructuring measures cardiac marker ntprobnp sustain longterm profit guide therapy heart ability failure patientsthe value innovationroche glance roche focus fitting treatments patients innovative medicines diagnostic tests global leader innovation sustainable company great workplace roche leader researchfocused committed sustainability driven shared set stan healthcare combined strengths running business way dards integrity courage reach pharmaceuticals diagnostics ethical responsible creates longterm beyond boundaries passion value countries patients treated employees research centres patients clinical trials manufacturing sites biotech oncology vitro diagnostics hospital market pharmaceuticals diagnostics worlds largest biotech company product global leader vitro diagnostic testing portfolio truly differentiated therapies robust pipeline early detection evaluation monitoring disease investigational new medicines also frontrunner management diabetes sales therapeutic area cer sales business area cer oncology professional diagnostics virology diabetes care inflammationautoimmune transplantation molecular diagnostics metabolismbone applied science ophthalmology tissue diagnostics respiratory diseases cardiovascular diseases renal anemia central nervous system infectious diseases therapeutic areas pharmaceuticals sales billion chf diagnostics sales billion chf roche group sales billion chf one roches topselling products fulltime equivalents fte cer constant exchange rates average fullyear strategic priorities patients need strive help patients need truly differ million cancer entiated diagnostics medicines focus lies five disease areas unmet medical need million hepatitis c oncology inflammation infectious disease metabolism central nervous system million schizophrenia million asthma million diabetes personalised healthcare personalised healthcare roche providing right therapy right group patients personalised right time provide medicines diagnostics pharmaceuticals diagnostics healthcare optimise patient care enabling tangible improve ments health quality life survival excellence science roche highly innovative healthcare company inhouse cutting edge science robust r foundation three autono mous research units well partnerships optimal resource allocation world foster diversity research translate science medicines external innovation innovative pricing models established roche aims bring medicines diagnostic markets pressure tests many patients need possible active payers explore innovative pricing models patient access schemes targeted individual markets emerging markets buildup healthcare systems tight cost parameters stakeholder value discovering developing innovative products patients employees aim provide value stakeholders patients doctors employees investors value society whole stakeholders shareholders providerstopselling pharmaceuticals millions chf product mabthera herceptin avastin pegasys xeloda rituxan sales growth cer active substance rituximab trastuzumab bevacizumab peginterferon alfaa capecitabine indications nonhodgkins lymphoma herpositive breast colorectal cancer breast hepatitis b c colorectal cancer chronic lymphocytic cancer advanced cancer nonsmall cell colon cancer leukemia rheumatoid positive stomach cancer lung cancer kidney breast cancer arthritis ancaasso cancer ovarian cancer ciated vasculitis glioblastoma cer constant exchange rates average fullyear topselling diagnostics millions chf accuchek nano smartview cobas e cobas c cobas taqman ventana ihc reagents product accuchek cobas e modules cobas c modules cobas ampliprep immunohistochemistry monitoring systems modular analytics modular analytics cobas taqman situ hybridisation elecsys cobas integra sales growth cer market segment blood glucose monitoring immunoassays clinical chemistry virology hepatitis b advanced tissue staining hepatitis c hiv business area diabetes care professional diagnostics professional diagnostics molecular diagnostics tissue diagnosticsthe value innovation roche global leader innovation medicines diagnostic testing annual report highlights inno vation brings value patients prescribers healthcare reimbursement society whole possible new medicine actemraroactemra highsensitivity herpositive meta relief agony childhood cardiac test static breast cancer arthritis precise testing life new generation cancer death decisions treatment accurate diagnosis working insurance cobas hpv cintec personalised healthcare industry china tests focusing healthcare budgets improving health insurance better screening cervical targeted treatments coverage cancer patients cancer special feature fight cancer goes mining biotech innovation pharma years cancer research roche r lono cn aoc lvh eae cti oop nne cn mrz e yb ae tir ng g value c olau rs lt dti ic n ha g e al c li ton hnd tu ribst ur ty ion oarifcu racshtscna ekde en gr ia f vy nr em c sc ide ed l csoo uh p rwy e ehn sv oen eaon ae l eat ab r nnts r h ovt sr e c eo dyht j ei ia u eh drt l r p u cl g ls ie eiie n elsn roi st e c e b c nes ro c ch pp u sfdon e ie f fa ilr r ee dd nf ol e oflo f c eei ilem yd mf eip ta r n ff r sfi le f ei tl ts e dgce r uhr de tn botn ue ha w et w l tt e e h clo ti r e etl eyo al nf un b lp uud lbi r n cnut roe sge eur ei hd efe nv vv h l f e e h e ea ge ra kha yrut trs l c ao spn h gi afsu vp ih itt rr tn r ha yot ta soe c h uyu r tb cf coa er gp ace en ct kfat nh e ae lhmc ac rlw taclne ne lf iaa c bb e yr cnd ia ti u n ec gad nc tf trs e r hfu haoc ce ener r r et en r ht e iili ra un oe ris sl ef l insg ni dl ie n e msi bct rnv ld w u ta ede eh rr h sgu ci r e c yy sw tds ho hi ne ir ae di tc l hy fdl ec lho ug cie tsf lher nt lpo c os ut aoy dc efi ih u r sm zea ta lis g neeh h enn cke dd dhoe ce fawtc srt codreh er fio ei n reo mt c nc esh c aa h pcs e n ut ceew rt nh tm r ese ahi e pts b co n toh tu ire eu os nd eil f lt rm e g le mt ba e wr et ter et rt h u r e nfo de ee n r r dpc ol rl ffu es shr nt r ie r uade eb ha tfn cee ueea til opr ng nnee rati epf cce nw n sr ooer n et goa mcn lad rfs nv yt es tnl e bigl et e sy av n sq e r eg ta e u il tnd co e e ha nvp tn pg ie na ho sve n r n r ec ecl od iy oa nc net l tt os se ro rs tfi tn eir ee f v dirt cg arh eev ia ota e e ac mt unrh e g iht na sd e aer e ti gl e e n hr dnpc c vsa te aa yu h st os ynm ttt e c f igo dc e aace ct eo sgn aln et casx nrt sd e ois c n ewuao v ef r ct erc ri e r sa hd er mf twn r abeu uuc gf e ce g bf yei tin hr ys years cancer research roche fight cancer goes special feature roche business report rochearoncofeatureengindd contents inside cover key figures roche glance key events letter chairman letter ceo management business review group results outlook market environment group strategy research development highlights accessing external innovation improving rd productivity pharmaceuticals pipeline manufacturing procurement pharmaceuticals manufacturing quality compliance diagnostics manufacturing procurement marketing distribution tailored market strategies innovative pricing models responsible business code conduct patient safety stakeholder engagement contributing public policy people building great workplace learning career development attracting retaining top talent embracing diversity community involvement humanitarian social projects arts culture science education community environment safety security health environment improving monitoring performance safeguarding employees property minimising environmental footprint pharmaceuticals environment corporate governance remuneration report corporate governance remuneration report independent assurance report letter shareholders franz b humer dear shareholders high levels public debt especially europe united states continued strength emerging economies two dominant influences healthcare sector bringing challenges opportunities overall demanding year industry one cost pressure many markets continued increase notwithstanding challenges roche posted good results year firm strategy developing medically differentiated medicines diagnostic products diseases areas high unmet medical need group sales increased constant exchange rates ing emerging market nations asia latin america billion swiss francs swiss francs roche already records fifth sales cancer cardio pharmaceuticals diagnostics divisions growing faster vascular disease among leading causes death respective markets roche delivered strong growth emerging economies demand medicines rising united states emerging markets whilst result actively expanding position asia europe continued feel pricing pressure healthcare latin america thereby improving global access medi budget cuts focus highvalue medicines diagnos cines diagnostics products tic tests however meant relative rest indus try sales europe held well optimised organisational structure past year adapting processes changing market environ general seeing increasing shift ment notable move closure roche site established markets especially europe faster grow nutley new jersey united states part conso roche business report letters shareholderslidation research earlystage development activities previously announced prof bruno gehrig lodewijk closing site easy decision nutley played j r de vink members board directors since pivotal role companys success past years decided stand reelection board directors next annual general meeting core operating profit improved significantly many years service made exceptionally valuable net income slightly higher billion swiss francs contributions growth company owe good operating performance offset costs associ debt gratitude ated number major restructuring programmes higher tax rate comparable basis core net income board directors proposes election dr severin previousyear period constant exchange rates schwan ceo roche group new member swiss francs board directors roche holding ltd enable board directors corporate executive committee another highlight year dow jones sustainability work together even closely help promote indexes naming roche supersector leader fourth con growth company todays challenging market environ secutive year ranking us worlds sustainable ment healthcare company two new corporate executive committee members leading way personalised healthcare announced second half recruited leader personalised healthcare roche uniquely posi within company daniel oday former chief operating tioned develop treatments raise current standards officer coo diagnostics division appointed coo care extend improve lives patients pharmaceuticals division effective september projects pharmaceuticals pipeline devel roland diggelmann former head asiapacific region oped conjunction companion diagnostic tests within roche diagnostics appointed new member strengthened personalised healthcare launching corporate executive committee daniel odays cancer medicines perjeta breast cancer zelboraf successor coo diagnostics division melanoma alongside companion diagnostics newly constituted form corporate executive com medical innovation benefits patients also mittee continue progress groups current strategic partners healthcare market payers economy course sustainably drive roches success global society general regrettably europe particular leader healthcare clinical differentiation key serving continues much focus costs shortterm think patients medical needs better safer costeffec ing harbours risk missing longerterm opportuni tive way even crucial increasingly cost ties economy society longerterm perspective sensitive environment tends neglected discussions rising health care costs contribution pharmaceuticals roche continue advance successful strategy diagnostics make medical progress focus innovation benefit patients physicians employees shareholders sustainable success applies roche business generally requires longterm thinking wardlooking investments innovation continue motor driving longterm success success story must continued open dialogue poli ticians industry franz b humer board propose swiss francs dividend chairman board view good results board directors propos ing dividend increase swiss francs per share nonvoting equity security swiss francs half net income distributed shareholders dividends subject approval th divi dend increase many years letters shareholders roche business report letter shareholders severin schwan dear shareholders difficult market environment company delivered strong performance continuing positive growth trend recent years met sales earnings targets importantly made significant strides product development three new roche cancer medicines approved last months new cancer drug also filed approval expand advances research develop core operating profit increased constant exchange ment would first like summarise key financial results rates billion swiss francs outpacing sales growth significantly group core operating profit margin rose sales pharmaceuticals division rose constant percentage points driven mainly productivity exchange rates billion swiss francs swiss gains cost savings francs growth driven cancer medicines herceptin mabtherarituxan avastin zelboraf well rheu core earnings per share key metric underlying business matoid arthritis drug actemraroactemra pegasys hepa performance excludes items global restruc titis c medicine tamiflu turing charges amortisation impairment intangible assets increased constant exchange rates diagnostics division consolidated global market lead original expectations ership sales billion swiss francs swiss francs driven strong demand clinical laborato achieving results would like thank employees ries immunoassays sophisticated blood tests diagnose hard work commitment professionalism range diseases also performed well continuing efforts continue make roche one worlds suc decadelong trajectory doubledigit growth cessful healthcare companies roche business report letters shareholdersbringing innovation patients maximising r productivity development pipeline key foundation roches future operationally restructuring pharmaceutical also showed healthy growth new search development activities order better allocate molecular entities clinical development overall resources improve efficiency resulted posi tive data trials drugs latestage clinical test difficult decision close roche site nutley new ing strengthening business innovative products jersey resulting savings site consolidation securing future years come diagnostics pipeline related infrastructure costs allow us reallocate resources remains solid new products launched key markets growing number clinical programmes whilst main taining stable r expenditure overall aware impact employees affected significant highlight extension roches closure families providing affected product portfolio treating highly aggressive herposi employees financial support professional advice tive form breast cancer backed decades research help prepare new job opportunities roche currently leading wave innovative developments combat severe tumours new breast cancer drug establish translational clinical research center perjeta approved us food drug administration new york keeping presence east coast june priority review therapy combinations united states center accommodate employ designed overcome treatment resistance whilst targeting ees support clinical trials early development pro multiple pathways cancer becoming grammes well continue collaborations academic important clinical trials show patients treated institutions biotech companies perjeta herceptin chemotherapy live significantly longer receiving standard therapy companion going forward convinced taken right diagnostic tests patients likely respond measures continue see benefits coming targeted medicines quickly identified overall expecting achieve sales growth constant exchange rates line roche adding group medicines filed regulatory groups results previous year target core earnings approval new drug antibodydrug conjugate known per share grow ahead sales based outlook trastuzumab emtansine tdm roche forefront antici pate able raise dividend developing antibodydrug conjugates adcs nine currently clinical development adcs combine speci ficity antibodies power chemotherapy targeting cancer cells directly significantly reducing side effects systemic chemotherapy risk death breast cancer patients receiving tdm shown trials lower receiving standard treatment severin schwan chief executive officer promising drugs also currently studied global pro grammes chronic lymphocytic leukemia nonhodgkins lymphoma potential improve mabthera rituxan current standard care fighting hematological tumours addition oncology roche also focusing dis ease areas high unmet medical need field neurosci ence alzheimers disease schizophrenia well metabolic inflammatory autoimmune diseases despite recent decision terminate dalcetrapib clinical pro gramme roche remains committed developing medicines patients cardiovascular disease diabetes dis covering developing new drugs means taking calculated risks road real innovation letters shareholders roche business report board directors dr franz b humer prof bruno gehrig andr hoffmann dr andreas oeri prof pius baschera prof sir john irving bell paul bulcke william burns lodewijk j r de vink dr christoph franz dame deanne julius dr arthur levinson board directors per december peter r voser prof beatrice weder di mauro roche business report managementboard directors name year birth term ends first elected board directors dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell b e paul bulcke b e william burns e lodewijk j r de vink b e dr christoph franz c e dame deanne julius b e dr arthur levinson c e dr andreas oeri e peter r voser c e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson board directors th annual general meeting agm roche holding ltd march shareholders reelected john bell andr hoffmann franz b humer members board directors term two years provided articles incorporation management roche business report corporate executive committee dr severin schwan daniel oday roland diggelmann dr alan hippe silvia ayyoubi dr gottlieb keller dr richard scheller dr mike burgess dr sophie kornowskibonnet corporate executive committee per december osamu nagayama dr stephan feldhaus roche business report managementcorporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group dr alan hippe chief financial officer daniel oday coo division roche pharmaceuticals roland diggelmann coo division roche diagnostics dr gottlieb keller general counsel silvia ayyoubi head group human resources enlarged corporate executive osamu nagayama chairman ceo chugai committee dr richard scheller head genentech research early development gred dr mike burgess head roche pharma research early development pred ad interim dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since chief compliance officer dr urs jaisli john c reed assume position head pharma research early development pred april become member enlarged corporate executive committee corporate executive committee sophie kornowskibonnet appointed head roche partnering joined enlarged corporate executive committee febru ary mike burgess assumed adinterim position head pharma research early development pred july became member enlarged corporate executive committee daniel oday appointed coo roche pharmaceuticals division roland diggelmann coo roche diagnostics division appointments effective september management roche business report value innovation possible new medicine herpositive metastatic breast cancer new generation cancer treatment treating cancer oncologists looking medicines deliver best results fewest side effects advance area could mean physicians may soon able prescribe treatment even effective better tolerated existing therapies latestage drug candidate trastuzumab emtansine tdm able deliver potent dose chemotherapy cancer cells chemotherapy linked active antibody could potentially reduce side effects traditional therapy devel oping drug limit impact chemotherapy provides true value pre scribers patients prof paul ellis guy 's hospital investigator emilia trial much hope patients actually need less traditional systemic cytotoxic chemotherapy exposed less way debilitating side effects normally associated agents think apart effectiveness one real legacies new types treatments tdm tdm tdm antibodydrug conjugate works potent cytotoxic agent dm drug made tras tuzumab chemotherapy stable linker called dm linker linker connects trastu monoclonal zumab dm tdm antibody trastuzumab binds herpositive cancer cells thought block outofcontrol signals make cancer grow also calling tdm binds receptor bodys immune system tumour cell surface initiating several antitu attack cancer cells mour activities absorbed tdm absorbed cell inside cell tdm breaks cancer cells releases active form dm dm designed destroy binds protein structure plays releasing dm key role cell division prevents cell dividing ultimately results cancer cell death web httpwwwrochecomvalueofinnovation trastuzumab active ingredient herceptin roche business report value innovation tdmenindd evolution therapy herpositive metastatic breast cancer chemotherapy targeted therapy highly targeted chemotherapy antibodydrug conjugates tdmenindd swiss francs core earnings per share roche business report business review reached financial targets delivered strong growth us emerging markets strengthened operating free cash flow lowered net debt improved r efficiency roche business report business review key figures group sales millions chf cer core operating profit millions chf cer net income millions chf cer millions chf changes sales cer chf usd group sales pharmaceuticals division diagnostics division core operating profit pharmaceuticals division diagnostics division operating free cash flow core earnings per share chf group results outlook roche delivered strong performance reaching emerging clinical product pipeline groups core operating financial targets year group sales increased margin improved percentage points billion swiss francs swiss francs reflected strong demand oncology products well clinical groups core earnings per share eps excludes laboratories diagnostic products us emerging noncore items global restructuring charges markets especially china brazil main regional amortisation impairment goodwill intangible assets growth drivers western europe however despite rose resilience pricing pressure sales slightly lower additional pressure generic competition roche took decision restructure pharma research early development make resources group core operating profit rose billion swiss available growing number products latestage francs due solid sales performance combined pro development closing nutley site process well ductivity improvements lowered cost sales ratio underway restructuring measures also taken r costs stable savings closure diabetes care applied science businesses enable nutley site new jersey usa reinvested strong units better adapt increasingly challenging market conditions cost restructuring activities together num unless otherwise stated growth rates calculated using constant exchange rates cer ber onetime items resulted slightly higher net roche business report business reviewincome ifrs basis billion swiss francs pharmaceuticals division sales region swiss francs united states pharmaceuticals western europe strong growth oncology japan sales pharmaceuticals division rose billion swiss francs robust demand three top international selling products mabtherarituxan herceptin avastin avastin also back growth supported launch constant exchange rates average fullyear ovarian cancer europe division additionally benefited strong demand rheumatoid arthritis medicine actemraroactemra product group strengthened showed superiority monotherapy adalimumab launch perjeta filing trastuzumab emtansine adacta trial well hepatitis c drug pegasys newly tdm new generation cancer treatment approval launched skin cancer medicine zelboraf also performed well europe us perjeta tdm allow roche year build longterm success herceptin standard care women herpositive metastatic breast cancer herceptin mabtherarituxan avastin actemraroactemra particularly aggressive form disease zelboraf pegasys together represent portfolio generated billion swiss francs additional sales pipeline remained robust delivering positive results year latestage studies including strong results avastin platinumresistant recurrent ovarian cancer two new cancer drugs also launched perjeta aurelia trial breast cancer erivedge advanced basal cell carcinoma type skin cancer initial uptake products positive sales eye medication lucentis wet agerelated macular pharmaceuticals division degeneration wamd fell competitive pressure sales growth e leading emerging markets intensified however uptake lucentis treat another indication diabetic macular edema strong bonviva brazil boniva cellcept sales also lower due ongoing generic erosion particularly western europe china regionally us sales along key seven emerging india markets main growth drivers strong demand oncology products well increased health mexico care spending number markets sales western europe impacted generic competition continued russia price pressure however major products including herceptin mabtherarituxan avastin continued grow south korea zelboraf emerged key growth driver japan posted sales growth year mircera avastin turkey mabthera performing strongly constant exchange rates average fullyear roches key seven emerging markets also referred e key emerging markets brazil china india mexico russia south korea turkey business review roche business report pharmaceuticals division core operating profit increased diagnostics division sales region billion swiss francs result strong sales efficiency gains core operating profit margin increased europe middle east africa emea north america diagnostics asiapacific strong clinical labs sales diagnostics sales increased billion swiss francs latin america continuing grow faster global ivd market showed slowdown market share roche japan solidly maintained market leadership divisional sales driven business clinical laboratories particularly constant exchange rates average fullyear professional diagnostics grew twice fast global market well tissue diagnostics molecular diagnostics near patient testing diabetes management well expanding test menus division also made largest overall product contributor growth progress personalised healthcare strategy immunoassay business helps diagnose various ongoing biomarker companion diagnostics projects diseases highly automated immunochemical blood roche pharmaceuticals new agreements con testing cluded external pharmaceutical companies diabetes care applied science businesses faced core operating profit diagnostics division fell challenging year reimbursement cuts blood glucose moni billion swiss francs reflecting increased price pressure toring products europe along intensified price pres diabetes care margin achieved sure impacted sales diabetes care business first six months year however percentage points decline sales applied science business lower result lower public research funding competition gene sequencing businesses undertook restructuring year sustain longterm profitability refocus strong group operating free cash portfolios future growth flow improved net debt position division consolidated expanded leading market posi operating free cash flow remained strong rising tion regions asiapacific latin america profes billion swiss francs contributing lower net sional diagnostics remained main growth driver debt position billion swiss francs end strong contributions diabetes care latin america billion francs start year result clinical laboratories business key growth driver strong cash flow bonds totalling nominal value north america launch major products billion euros bought back early us started create growth momentum emea region europe middle east africa austerity mea sures pricing pressure impact sales particularly outlook diabetes care japan sales grew three times rate market driven professional diagnostics roche expects group sales increase line sales growth recorded constant exchange rates division launched major products key markets core eps targeted grow ahead sales roche expects year representing important advances lab automation increase dividend estimated ivd market growth source company independent reports end september roche business report business reviewmarket environment group strategy healthcare market continues driven compet challenges ing pressures supply financial resources ever increasing demand better healthcare outcomes cost rising life expectancy higher incidences chronic dis effective targeted medicines diagnostics like eases significantly increased need rapid scientific produced roche key role play tackling technological advances better health outcomes challenges market trends affluent west constitute fastest growing public health problems developing countries despite advances modern medicine need improved healthcare treatments remains enormous pharmaceutical market known diseases twothirds remain untreatable pharmaceutical markets continuing expand world lack satisfactory treatment growing ageing world wide although pace growth slowing population meanwhile accelerating demand medicines going patent global sales forecast andolder population forecast triple billion reach trillion swiss francs giving rise agerelated chronic diseases cancer diabetes alzheimers disease ageing emerging markets showing robust growth cre lifestylerelated diseases longer problem ating new opportunities pharmaceutical industry governments invest public healthcare systems china expected main contributor global growth regional market share global pharma sales growth developed markets however expected stay modest best us largest healthcare market usa growth rates forecast slow lower gdp growth increasing generic competition europe speciality pharmaceutical markets largest among china fastest growing healthcare segments total market share data source ims largest share japan growth us key growth areas oncology brazil russia autoimmune disease general hospital biolog india ics segments roche global leader canada diagnostics market global vitro diagnostics market estimated approxi rest world mately billion swiss francs grown slower pace expected grow average rest emerging markets annually longer term source independent ivd consultancy highest growth rates forecast ims health market prognosis april emerging markets molecular tissue diagnostics business review roche business report global need new better treatment options diagnostics division working support develop increases pressure control healthcare ment reimbursement programmes accurately assess costs us europe particular economic conditions validity advanced diagnostic testing driving cost efficiency measures putting pressure healthcare industry deliver innovative solutions lower costs business model changing practice medicine us additional conditions introduced regula tory process approval new medicines new legislation decade roche maintained strategic focus encourages comparison medical treatments innovative diagnostics therapeutics today basis safety efficacy additionally intensifying commitment develop personalised health cost increasing influence nonprescribing decision care medically differentiated products medicines makers evident markets uk ger diagnostics create superior value patients many staterun organisations reviewing clinical customers society advance goal focus exclu wider economic benefit new medicines comparison sively prescription pharmaceuticals vitro diagnostics established products market health technology following business model drives medical innovation assessments becoming common europe along three dimensions us evaluate reimbursement decisions medical evidence fitting treatments patients comes frequently valuebased pricing systems pursuing excellence science payment structured around treatment outcome delivering value stakeholders health systems around globe generally increasing focus clinical outcome real world evidence data fitting treatments patients enable real value new medicines assessed eighteen million patients treated roche medicines product launch pharmaceutical industry also active last year patients participated clinical working health authorities structure clinical trials trials new drugs developing patient frames provide evidence medical value quickly inno strategy discovering developing new medicines vative medicines reach patients quickly diagnostics deciding molecules research design clinical trials focusing innovation new diagnostic techniques enabled us develop thera pies increasingly targeted particular patient researchbased healthcare company roche focuses populations two patients diagnosis yet innovation investing significantly r develop highly dif respond different ways medicine one patient ferentiated effective treatments help people live longer may helped treatment experiences healthier lives personalised healthcare roche one unwanted side effects without desired clinical benefit example strategy pinpointing exactly patients mostly variability due genetic biological respond particular therapy ensures patients differences patients receive right treatment right time without wast age healthcare budgets targeted approach delivers drawing insights differences molecular value healthcare stakeholders patients providers reg level develop treatments tests tailored ulators payers effective diagnostic testing also plays needs specific patient populations personalised important role increasing overall efficiency healthcare approach enormous potential make healthcare better delivery although spending vitro diagnostics repre safer costeffective additionally medically sents around healthcare expenditure medical differentiated products likely obtain regulatory decisions depend accurate fast diagnosis approval accepted patients physicians payers turn reduce healthcare costs considerably owing significant clinical benefits roches new cancer demonstrating value strategic priority roche medicines erivedge zelboraf perjeta received accelerated collaborate extensively healthcare providers insurers approval first markets latter two approved payers particular value timely accurate companion diagnostic today roughly half new molecular diagnosis always fully recognised entities latestage portfolio tailored subsets roche business report business reviewpatients identified using diagnostic tests productivity research development last two central personalised healthcare years roche achieved positive latestage trials success rate clearly industryaverage pursuing excellence science excellence science discovery innovation combine strong inhouse research capabilities answer medical challenges world faces continu latest advances science biotech companies ously investing research development seek gain partnerships today onethird pipeline better understanding disease harness potential marketed products originated external net modern biological sciences treating diseases work also foster innovation interacting academic roche invested billion swiss francs institutions universities worldwide r past ten years com panies world delivering value stakeholders since formation roches valuable contribution sciences rapidly expanding knowledge disease biology society discovery development novel causes disease hold particular promise transforming therapies improve health help patients live longer practice medicine knowledge leading better lives dramatic improvements identifying biological targets fight many diseases complexity research rising signifi continued success hinges largely ability combine cantly resulting lengthy costly r cycles social environmental responsibility focus sus new products years approximately billion tainable economic growth roche convinced sustain swiss francs average obtain approval new drug able corporate policies practices promote innovation time increasingly stringent regulation slowing create longterm value among stakeholders approval new molecular entities industry whole patients doctors ensuring product quality safety improving access medication enabling medical excelling science achieve breakthroughs laboratories work efficiently helping contain science technology needed speed discovery healthcare costs development approval new medicines interweaving employees giving people opportunities make knowledge pharmaceuticals diagnostics divi mark improve lives creating great places work sions throughout value chain increases efficiency embracing diversity across organisation roche strategy leveraging pharmaceuticals diagnostics throughout discovery market pharmaceuticals research development commercialisation unrestricted knowhow efficient faster adoption phc solutions ip exchange development medicine test technically validated clinically validated research assay ivd assay ivd assay diagnostics business review roche business report investors ensuring transparency achieving superior structure built innovation valuations industry peers aiming provide mastering complex biology various diseases total shareholder return top quartile industry pathways biggest challenge developing new diagnostic peer set tests medicines overcome challenge communities stimulating engagement science pro encourage people consider different perspectives moting cultural activities tackling social causes approaches drug research early development make lasting impact also structure business foster creativity excellence society large conducting businesses responsibly science view positive influence society minimis ing impact environment roche recognised two complementary inhouse research early develop supersector leader healthcare fourth time ment arms pred gred well roche diagnostics row dow jones sustainability indexes chugai operate independently within group believe decentralised approach combines critical mass roche group flexibility creativity management model enabling entrepreneurial spirit common among smaller busi innovationdriven culture nesses time consolidate coordinate groupwide activities clinical development manufacturing management model aimed enabling culture inno marketing commercial operations make best use vation embracing diversity approaches like busi global scale reach ness model three dimensions inspiring integrity courage passion among people encouraging accountable transparent decision making structuring business capitalise innovation people integrity courage passion ability leverage combined expertise pharmaceu ticals diagnostics ultimately depends people rep resenting virtually every country globe employees bring work diversity perspec tives experiences stimulates creativity innovation respect embrace value diversity actively fos ter high standards integrity courage reach beyond boundaries passion improve patients lives integrity passion courage values seek company bind us together team constantly grow decision making accountable transparent believe good leadership question hierarchy function effective decision making given highly networked organisation complex nature busi ness decisions must informed dialogue system atic factbased open transparent every decision requires single accountable decision maker collects criti cally reviews information competing views empowerment essential delegate decision making much possible lowest qualified level organi sation roche business report business reviewspecial feature fight cancer goes years cancer research roche one three people develop cancer lifetime start aim advance treatment cancer yet challenge find cure remains elusive one result roche later developed several successor drugs reasons difficult treat cancer strictly speak aim preferentially generating cytotoxin fu ing one disease group different diseases tumour consequently achieving greater effi far different types identified cacy fewer side effects cers common though caused uncontrolled proliferation human cells since early beginnings cancer research conducted roche others provided doctors patients bet roche forefront cancer research dec ter better medicines diagnostic agents ades today leading pharmaceutical diagnostic company field well years ago robert duschin cancer cells unfortunately inventive discover ways sky see picture nutley collaboration charles escaping treatment often reproliferating later stage heidelberger university wisconsin synthesized despite tremendous progress treatment cancer much fluorouracil fu roches first anticancer drug although remains done combat insidious disease considered breakthrough time caused severe side effects attacks healthy cells cancer cells special feature roche business report longrunning battle cancer contributions diagnostic tumour markers global guidelines pain cancer mortality starts decline blood management intensive exposure sunlight radiotherapy chemotherapy treatment earlystage colon recognised cause skin cat scan cancer cancer viruses cause cancer hpv medicines increasing red natural cytostatics used breastconserving surgery blood cell production patients cancer treatment anemia first targeted biopharmaceuticals first cancer medicines produced relationship demonstrated biotechnology obesity cancer foundations molecular molecular diagnostic tests advance diagnostics cancer detection fluorouracil first enzyme immunoassay epoetin beta fu synthetic substance roche detection tumour antigens neorecormon inhibits cell growth treatment chemotherapy administered intravenously induced anemia causes tumours shrink alphainterferon roferona attacks dividing cells roches first biotechnological including healthy ones product approved treatment filgrastrim neupogen previously fatal form blood cancer prevents white blood cell depletion positive response rate risk infection chemotherapy procarbazine natulan cases treatment lymph tissue tumours retinoic acid vesanoid active substance interferes genetic treatment acute promyelocytic material dna disrupts doxifluridine leukemia cell division furtulon devel opment fu designed rituximab generate active fu prefer mabthera first tar entially tumours resulting geted biotechnologically fewer side effects produced drug used treatment nonhodgkins fluorodeoxyuridine lymphoma blood cancer floxuridine fu derivative indications capecitabine xeloda orally adminis tered inactive precursor fu designed generate efudix cream containing fu doxifluridine absorbed local treatment skin tumours gut thereby reducing risk intestinal damage worlds first immuno trastuzumab diagnostic test tumour marker herceptin biotechnologi cea carcinoembryonic antigen cal drug treatment particularly aggressive positive form breast cancer accounting breast cancers high protein levels must first detected companion diag nostic test treatment first example medicine geared needs specific patient group personalised healthcare roche business report special features decoding human genome record number cancer survivors cancer cells become resistant firstline drugs breakthrough medicines skin cancer combination treatments targeted drugs new drug class antibodydrug conjugates first medicine inhibit tumour blood supply personalised cancer therapies cervical cancer vaccine companion diagnostic tests genetic tissue cancer tests combination treatments resistance bevacizumab avastin first biotech vemurafenib zelboraf compan nological cancer drug block angiogenesis ion brafve mutation detection test words formation blood vessels mutated form braf protein occurs supply cancer tissue nutrients oxygen half melanoma patients companion specifically blocks naturally occurring protein test identifies patients specific mutation vegf vascular endothelial growth factor zelboraf launches targeted attack important mediator angiogenesis avastin pos tumour making first treatment aggres sesses novel mechanism action used sive skin cancer considerably improve quality several types tumours life prolong survival erlotinib tarceva oral lung cancer eight important new oncology tests drug inhibits tumour development attacking including cobas hpvin us detect women heregfr protein important cell increased risk cervical cancer growth vismodegib erivedge oral targeted drug treatment advanced inoperable metastatic basal cell carcinoma erivedge specifi cally blocks mediator hyperactive signal path way cancer cells pertuzumab perjeta biotechnological drug treatment particularly aggressive form breast cancer positive combination chemotherapy herceptin dimerisation inhibitor designed specifically prevent receptor pairing receptors special feature roche business report cancer growing global challenge cancer remains unconquered cardiovascular disease cancerrelated deaths claims victims year almost million people world worldwide wide diagnosed cancer around eight million people die annually form cancer developing coun tries account half cases cancer kills lung people year aids malaria tuberculosis combined stomach cancers increase chiefly growing liver ageing world population breast lung prostate cancers frequently diagnosed industrialised countries colorectal unhealthy lifestyle choices also contributing increase breast cancers estimated cancers could prevented avoiding behaviours smoking alcohol abuse conditions like overweight recent progress diagnosis treatment cancer contributed encouraging overall improvement survival medically promising approaches include better early detection rates even advanced cases survival breast cancer combination treatment regimens different patients example almost tripled effects attack tumour new angles today targeted medicines effects adapted genetic changes tumours ushering new era cancer therapy currently every year million people diagnosed cancer estimated age standardised incidence rate per cancers excluding nonmelanoma skin cancer sexes ages reference international agency research cancer globocan cancer fact sheet accessed online httpglobocaniarcfr roche business report special featuregaining better understanding insidious disease cancer difficult control important finding signal chains whose function disrupted mutations research molecular level cancer collective corresponding genes often involving antennas term tumours affect cell membrane cell surface receptors bodys tissues occasion multitude signs symp partly responsible controlling signal pathways trigger toms late effects ing cell division multiplication become hyperactive lead ing uncontrolled cell division proliferating cells ultimately types cancer due damage dna displace damage healthy tissue hence changes genes genetic defects cause tumours extent inherited often however researchers roche working identifying characteris acquired course life cancerengendering tic changes genome signalling pathways substances tobacco viruses radioactive rays particular tumour aim combat cancer damage genes hence cells blueprints effectively blocking overactive mechanisms tumours develop mainly cells displaying gene changes mutations changes affect important cellular mechanisms normally control cell proliferation signal pathways triggering cell division proliferation cancer pathways often disrupted rtk pip pip pten ras pa p pik tsc raf akt tsc mek erk cyclin forkhead bad mtor cell cycle proteinsynthesis p fasl bcl progression growth proliferation survival special feature roche business report improving survival benefits cancer patients advances cancer medicine last ten years pro survival benefits new cancer medicines may better longed life improved quality life considerably cancer indicated however new treatments initially used patients ten years ago patients advanced breast cancer advanced stages disease unfortunately patients lived months diagnosis average today live situation often already experienced series treat almost three times long ment failures lead understatement sur vival benefits new medicines progression overall survival average months advanced cancers last decade lung cancer glioblastoma colon cancer kidney cancer gastrointestinal stromal tumours breast cancer ear nose throat cancer multiple myeloma malignant bcell lymphomas months year old treatments new treatments average values variety treatments source prof christoph zielinski university vienna march optimising outcome treatment malignant disease using modern treatment strategies impact cancer patient survival httpwwwonkologiewienatforschungundlehrepositionspapier roche business report special featurepromising research cancer treatments future roche direct four billion swiss francs annually gearing human immune system attack tumour cells oncology research entire expenditure r effectively pdl antibody blocks pdl protein found many tumours prevents immune pursuing variety strategies gaining increas system cells destroying malignant cells ingly better molecular understanding cancer leading glycoengineered antibody ga first binds improved detection new broader treatments tumour cells attracts immune system cells recent advances include tlymphocytes natural killer cells destroy drug combinations block array signal pathways flagged tumour cells spiral control cancer thereby preventing development resistance tumour cells targeted therapeutic agents combined new type targeted selective cancer therapy anti companion diagnostic test predicts probability bodydrug conjugates kills cancer cells exerts patient responding treatment personalised approach minor negative effects normal tissue cancer treatment better patients also enables efficient use financial human resources national health systems roches oncology portfolio broad set technologies targeted therapies tumour types gastric colorectal lung skin gliobla hema positive negative stoma tological breast breast antibodydrug tdm tdm anticd conjugates anticd b antibody perjeta perjeta metmab metmab metmab metmab combinations herceptin herceptin avastin avastin avastin avastin egfl egfl avastin avastin glycoengineered ga ga ga antibodies obinutuzumab immuno eg zelboraf therapies pdl small pik pik zelboraf bcl molecules meki pik special feature roche business report experts view susanne arbogast pathologist oncology franchise roche projects designed produce new cancer drug combined biomarker programme probing analyses begin preclinical stage lead licensed diagnostic tests put pioneering use primarily phase iii projects fact number biomarker studies conduct collaboration external part ners also inhouse considerably exceeds number pharma projects exploring several avenues simultaneously classifying markers give insights response particular therapy thus screening patients tumour samples differ ences level genes dna molecules transfer genetic information rna gene products proteins cancer diagnostics appear set evolve single test approach simultaneous testing several parameters order identify best possible treatment particular patient roche business report special featurehal barron chief medical officer progress oncology therapeutic areas last two years incredibly robust addition receiving regulatory approval three new molecular entities cancer less months results key clinical trials oncology nononcology medicines positive results success rate means basically every three weeks news results meaningful impact patients likely many factors contributed successful studies including rigourous early research efficient study execution smart risks focus personalised healthcare identify patients likely benefit certain medicines combined measures talented people increase probability technical success allow us deliver transforming medicines patients special feature roche business report collaborations pharmaceuticals diagnostics roche business report research development received approvals three new cancer medicines delivered positive results latestage clinical trials continued clinical development promising new molecular entities launched diagnostic products key markets roche business report research development key figures core research development r expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sales diagnostics millions chf cer sales employees r roche group pharmaceuticals diagnostics constant exchange rates average fullyear highlights pharmaceuticals milestone compound indication approvals us erivedge advanced basal cell carcinoma perjeta metastatic breast cancer approvals eu zelboraf braf v mutationpositive metastatic melanoma avastin recurrent platinumsensitive ovarian cancer filings us tdm metastatic breast cancer filings eu perjeta metastatic breast cancer tdm metastatic breast cancer key phase iii trial results emilia tdm adds nearly six months average lives women herpositive metastatic breast cancer second line cleopatra perjeta significantly extends lives herpositive metastatic breast cancer patients given new drug alongside herceptin chemotherapy first line adacta actemraroactemra shown effective adalimumab monotherapy rheumatoid arthritis diagnostics major product launches major launches including three devices people diabetes three instruments pointofcare testing eleven systems driving efficiency clinical research labs assays diagnosis cancers infections metabolic diseases key clinical study results vision troponin cardiac test helps identify patients risk major noncardiac surgery abacus accuchek aviva experts bolus advisor helps people diabetes improve ability reach glycemic targets roche business report research developmentour pipeline remained solid delivering positive results longer given herceptin chemother latestage studies total apy study also showed risk death cut new molecular entities clinical development con third fident several compounds become important therapies coming years latestage emilia trial showed patients positive metastatic breast cancer already received diagnostics division launched major products key treatment illness survived median months markets including three diabetes care devices vitamin longer treated tdm received test united states lapatinib xeloda risk death reduced third highlight ability improve treat trials ongoing examine use perjeta ment options available women suffering herpositive tdm women earlier stages herpositive breast breast cancer particularly aggressive form disease cancer also examining combination perjeta year around million women diagnosed breast tdm cancer across world die disease herpositive breast cancer affects approximately herceptin perjeta tdm work targeting women breast cancer women must tested see receptor protein found abnormally high quantities whether type breast cancer outside cancer cells herpositive cancers perjeta herceptin complementary building success herceptin past years target receptor different places tdm par launched new medicine perjeta united states ticularly interesting compound one first secured positive recommendation european unions examples antibodydrug conjugate adc new tech committee medicinal products human use also nology could make significant difference cancer treat filed approval novel therapy trastuzumab emtansine ment see tdm europe united states data late stage trials shown drugs could make disappointment second interim analysis real difference many women diagnosed daloutcomes phase iii trial showed lack positive breast cancer year clinically meaningful efficacy dalcetrapib drug aimed reduce risk cardiac events heart attack cleopatra phase iii study showed women raising highdensity cholesterol decided stop devel herpositive metastatic breast cancer treated opment dalcetrapib basis data perjeta herceptin chemotherapy lived significantly fighting herpositive herceptin also used treat women breast cancer earlier stages herpositive breast cancer given women type breast cancer great deal hope decade ago women diagnosed survival rates significantly improved many women positive breast cancer faced bleak future survival rates treated herceptin early stages patients type cancer among worst illness live disease free several years treatment death would likely follow within three years diagnosis million people treated herceptin scientists discovered overexpression gene known human epidermal growth factor receptor story approval perjeta blame deadly form breast cancer strong data tdm next chapter beginning began develop targeted therapeutic antibody would block hergrowth factor receptors eventu ally herceptin approved women latestage includes patients treated herceptin breast cancer herpositive breast cancer stomach cancer research development roche business report antibodydrug conjugates adcs extensive pipeline adcs oncology indications adcs allow patients get benefits chemotherapy indication phase iii registration without suffer many toxic side effects chemo therapy works attacking healthy cancer breast tdm ous cells know securely attach chemo therapy antibodies allows targeted delivery nhl anticdrg chemotherapy cancer cells increase efficacy may decrease side effects chemotherapy nhl anticdbrg hair loss nausea infection prostate antisteaprg tdm made trastuzumab active ingre dient herceptin potent chemotherapy agent dm ovarian rg linker connects dm trastuzumab multiple myeloma rg roche currently eight adcs clinical development ten oncology indications optimistic soon lung ovarian rg able replicate success tdm various types cancer blood cancer pancreatic ovarian rg melanoma rg diagnostics ahdowc sa dhcows w thoeryk work cceerrttaaiinn pprrootteeiinnss tthhaatt aarree nnoott ffoouunndd eellsseewwhheerree iinn tthhee bbooddyy tmhaei nm cahina lclehnagllee nisg ee niss uerninsgur tinhgat tthhaet cthhee mchoethmeortahpeyr aisp py rios p ccaann ssoommeettiimmeess bbee ffoouunndd oonn tthhee ssuurrffaaccee ooff ttuummoouurr cceellllss bbyy erly partotapcehrelyd ttota tchhee adn ttoib tohdey anntdib tohdayt aitn wdi ltlh naot ti tf awlli lol fnf oint ftahlel ff ddeevveellooppiinngg aann aannttiibbooddyy tthhaatt rreeccooggnniisseess tthheessee pprrootteeininss anndd blooidn tsht ec belrotaoidn sptrroetaemin nthda atc atr jeu snto lti kfeo ucnhde melosethwehraeprey nif tthheis aattttaacchhiinngg tthhee cchheemmootthheerraappyy ttoo tthhee aannttiibbooddyy iitt iiss ppoossssiibbllee bodhy acpapne snosm theeti mpaetsi ebnet fdoouensd noont tgheet saunryf abceen oeff itt ufmroomu rt hcee ltles ch dtoe ldiveelirv ae rt oax tionx dinir edcirtelyc ttoly tthoe hcaen ccaenrc ceerl lc aenlld pnodt penottieanlltyi aslplya reamn oalnodg yac rt ijcuhsta rlidk es cchheelmleort hheeraadp yof igf rtheisd h saapidpe ntsh itsh apsa tkieeny tshpea rree stht eo fr ethset obfo tdhye fbroomdy hfreo mim tphaec itm opf athcet ocfy tthoeto cxyicto dtoruxgic doesto n soet cguerti nagn yt bdenmefist fsruocmc ethses technology richard scheller cdhruegm ootrh cehraepmyotherapy head gred said key securing tdms success stable linker receptor chemotherapy agent dm monoclonal antibody trastuzumab cancer cell step step step trastuzumab component tdm detects trastuzumab component blocks cell tdm degraded releasing binds herpositive cancer cell ofcontrol signals make cancer grow active dm form binds also calling upon bodys immune protein structure playing key role cell divi system attack cancer cells tdm sion dm prevents cell dividing taken herpositive cancer cell cell dies roche business report research development tdmenindd blood cancer introduction hematology working next generation targeted therapies common blood cancer lymphoma occurs treat certain blood cancers like nonhodgkins lymphoma lymphocytes type white blood cell grow abnor nhl chronic lymphocytic leukemia cll mabthera mally two main types lymphocytes develop lym known rituxan united states proven phomas blymphocytes bcells tlymphocytes extremely effective medicine hematological cancers tcells cancerous lymphocytes travel many parts since launch used treat around body including lymph nodes spleen bone mar million patients oncology row blood organs still however unmet medical need area patient tested cd protein surface drawing understanding biology bcells bcells find whether bcell tcell role blood cancers developing number derived cancer mabtherarituxan works targeting compounds could improve treatment hema bcells high levels cd growing tological cancers abnormally obinutuzumab ga designed even ef two main types lymphoma nonhodgkins lym fective drug mabtherarituxan obinutuzumab works phoma hodgkins lymphoma nhl common targeting cd protein malignant bcells binding cancer lymphatic system part immune cell surface way restores natural process system expected nearly cell death apoptosis time activates bodys annual deaths worldwide nonhodgkins lym immune system aid cell death process known phoma antibodydependent cellmediated cytotoxicity adcc obinutuzumabs clinical development programme designed demonstrate superiority mabtherarituxan multiple frontline headtohead trials nhl cll first phase rg selective inhibitor pmdm binding iii trial report cll stage results looking gene p plays central role controlling cell growth use firstline cll due recruitment obinutu division helps suppress tumours scientists tried zumabs phase iii trials going well find ways restoring function ps gene product known p damaged one way rg inhibits bcl protein highly expressed mdm gene gene works p cll indolent nonhodgkin lymphoma aggressive keep division cells control preventing exces lymphomas well bcell neoplasms data sive production p drugs target mdm could phase trial presented american society hema fore allow body produce p restore normal tology ash annual meeting showed antitumour activ cell growth phase results presented ash provided proof ity patients mantle cell lymphoma mcl diffuse large mechanism evidence singleagent clinical activity bcell lymphoma dlbcl follicular lymphoma walden mdm antagonism leukemia demonstrating complete stroem macroglobulinemia wm remission maximum tolerated dose lysis leukemic blasts activation p pathway targets also developing adcs target cdb cd leukemic cells two additional antigens expressed nearly bcell lymphomas phase data presented anticdb adc rg anticd adc rg ash showed targeted therapies two compounds promising antitumour activity acceptable tolerability profile heavily pretreated roche forging ahead development therapies patients relapsed refractory bcell nhl including target abnormal gene expression diseases like cancer follicular lymphoma dlbcl mcl headtohead phase onartuzumab metmab one many promising compounds ii trial looking two agents combined rituximab pipeline ongoing adcs developed using seattle genetics technology research development roche business report onartuzumab targeted therapy could used combination therapies number different cancers including lung cancer breast cancer colorectal cancer glioblastoma type brain tumour combination cancer medicines emerging one gastric cancer results far strongly suggest onar important effective ways help people cancer tuzumab works best patients express met protein live longer combining treatments possible hit several investigated latestage trial use metposi pathways responsible tumours growth also means tive advanced nonsmall cell lung cancer combination medicines able overcome resistance cancer tarceva one existing lung cancer therapies mid may built certain treatment stage results presented showed combination onartuzumab tarceva tripled time braf meki building extensive clinical experi metpositive patients lived compared tarceva alone ence firstinclass braf inhibitor zelboraf investi gate number combination approaches including zelboraf onartuzumab works stopping protein called hepato investigational mek inhibitor gdc scien cyte growth factor hgf binding met stopping tists believe one reason patients treated met hgf coming together cancerous cells find braf inhibitors stop responding therapy difficult grow replicate survive spread acquired resistance drugs inhibit rasraf also developing tissuebased companion diagnostic test pathway initiated phase iii study exploring cmet allow doctors identify likely potential investigational mek inhibitor gdc benefit onartuzumab zelboraf avastin onartuzumab preclinical studies shown combination avastin onartuzumab syn ergistic effect attacking cancer cell growth avastin works targeting inhibiting vascular endothelial growth companion diagnostic tests factor vegf required growth new blood vessels blocking vegf avastin starves tumours diagnostics plays key role research develop blood supply onartuzumab targets met receptor ment targeted medicines per also drives vegf expression phase ib study combina sonalised healthcare collaborations within group tion avastin onartuzumab generally well tolerated pharmaceuticals pipeline projects roche looking simultaneous targeting vegf developed companion diagnostics met pathways across various tumour types including tri ple negative breast cancer metastatic colorectal cancer glio diagnostics divisions tests allow researchers blastoma nonsmall cell lung cancer accurately identify molecular abnormalities causing dis ease allows researchers make drug tailored specific patients result drug effective looking future oncology therapy dosing optimal reducing unnecessary side effects roche working new type cancer treatment combination specific diagnostic tests targeted restore patients immune system attack therapies already improved prognosis many cancer tumour antipdl roches first cancer immunotherapy patients companion diagnostic tests also helped programme clinical development goal significantly treatment infectious diseases like hepatitis c improve durable survival number human cancers anti pdl human monoclonal antibody engineered restore working diagnostic testing shed patients existing immunity generate new immunity light certain tumours become resistant targeted drug therapy roche uniquely positioned leader cancer immuno therapy based wealth experience knowledge roche confident also able use com immunology oncology continue research panion diagnostics number disease areas apart develop antipdl molecule monotherapy cancer immunology neuroscience combinations treatments incorporating bio roche business report research developmentongoing combination therapy trials phase phase ii phase iii launched antipdl avastin onartuzumab avastin perjeta herceptin perjeta herceptin solid tumours triple neg mbc adjuvant herpositive herpositive bc mcrc bc aphinity nsclc nonsquamous l recurrent glioblastoma antipdl antiegfl avastin tdm perjeta zelboraf braf nsclc l herpositive bc l metastatic melanoma mcrc l marianne braf mut herpositive bc ebc anticd adc anticdb adc mabthera hematologic malignancies zelboraf braf meki rg marker research enhance understanding science behind cancer immunotherapy treating untreatable another new way treating cancer future could come roche developing therapies number central rather unexpected source toxins bacterial nervous system cns disorders recently infection exotoxins exotoxins kill cells one believed untreatable particular pseudomonas exotoxin pe could prove important agent treatment cancer extremely people autism example traditional potent cell killer far toxins proven impossible thinking nothing could done luca santarelli harness therapeutic usage bodys immune head neuroscience said system always rejected new data shown medicines could also developed collaboration national cancer insitute nci illnesses autism fragile x syndrome downs exploring use deimmunised version pe war syndrome refractory depression well early stages head attached antibody fragments peptidergic binders alzheimers disease whole molecule called cytolytic fusion protein cfp several agents development one strongest neuroscience pipelines advanced targeted pleural mesothelioma cancer industry roche made considerable progress area treatment options aim first cfps last decade group nearly dozen humans results clinical proof con compounds development cns cept able quickly develop number followon molecules targeting different cancers allowing us take shortcuts cns development santarelli advantage flexibility platform said gantenerumab alzheimers ten years making neuroscience working closely academic institutes external bio tech companies well forming publicprivate partner past ten years scientists gained better ships helped roche develop presence field standing brain today roche working new mole development companion diagnostics also cular entities could become next generation medi critical particularly alzheimers cines range diseases including schizophrenia multiple difficult disease diagnose properly research development roche business report sclerosis depression neurodevelopmental disorders parkin gantenerumab significantly decrease levels amyloid sons disease alzheimers disease brain currently conducting phase iiiii trial gantenerumab called scarlet road used c ompanion tackling diseases central nervous system cns diagnostic identify patients early ensure focusing biology illness taking similar patients enrolled display alzheimers disease pathology approach development cancer therapies biomarkers first results scarlet road expected also helping us develop targeted treatments cns disorders alzheimers gantenerumab one three compounds selected worldwide trial investigating whether antiamyloid agents prevent alzheimers dominantly inherited alzheimer alzheimers disease network trial conducted washington university school medicine st louis usa two advanced compounds treatment alzheimers gantenerumab crenezumab crenezumab two phase ii trials abby blaze mild moderate alzheimers results trials due gantenerumab aiming treat patients alz crenezumab also part us government heimers around five years earlier currently backed trial preclinical alzheimers determine whether treated slow even prevent could help prevent slow disease study investi damage brain gantenerumab initially devel gating use crenezumab group around colom oped partnership morphosys investigated bians genetic mutation results developing patients prodromal alzheimers showing signs alzheimers forties far drug shown side mild cognitive impairment evidence amyloid effects meaning used higher doses potentially plaques brain early clinical studies shown increasing amount gets brain crenezumab antibody targets solid bits beta amyloid make plaques brain freefloating soluble forms abeta protein alzheimers disease alzheimers devastating impact lives patients schizophrenia families common form dementia approximately million people suffer alzheimers roche working improve lives people schizo worldwide estimated million people phrenia chronic brain disease affects approximately affected many million people could million people among common disabling disease population ages conditions worldwide symptoms schizophrenia fall three main categories positive symptoms hallu alzheimers notable clinical symptoms common cinations delusions negative symptoms lack people age people certain rare speech lack emotional expression inability begin genetic mutations may develop disease earlier sustain activities social withdrawal cognitive deficits include difficulties memory attention decision people alzheimers abnormal amounts amyloid making reduced signalling nmda nmethyld protein amyloid plaque brain buildup protein aspartate receptor thought possible explanation reduces effectiveness healthy neurons gradually symptoms destroys detecting levels protein spinal fluid used identify patients alzheimers bitopertin new firstinclass oral glycine reuptake inhib high risk converting dementia itor designed improve nmda receptor function years time phase iii trials searchlyte trial programme investi gating bitopertin combination standard care anti believe approach treating alzheimers early psychotics patients predominant negative symptoms stages prodromal pioneering roche currently four daylyte flashlyte sunlyte suboptimally compounds clinical development alzheimers controlled symptoms schizophrenia moonlyte twilyte nightlyte roche business report research developmentidentifying risk multiple sclerosis developing ocrelizumab new therapy multiple developing immunoassay identify sclerosis ms debilitating neurological illness ocrelizumab patients higher risk developing alzheimers humanised monoclonal antibody designed selectively disease also developing genetic test apoliprotein target cdpositive bcells thought play e identify carriers apoe genotype may important role ms works bodys immune system benefit dose adjustment gantenerumab well eliminate cdpositive bcells ocrelizumab phase another immunoassay tau used iii clinical trials patients relapsing form dis exploratory surrogate marker efficacy ease opera ii patients primary progres sive form ms oratorio approved immunoassay various techniques determining treatment levels antigen antibody oxford medical dictionary diagnostics diagnostics division made advances lab automa developing new technologies tion near patient testing diabetes management newly launched tests aiding diagnosis cancers investing new technologies could make infectious diseases metabolic disorders important difference way certain diseases cancer diagnosed two examples microrna united states largest market launched vitamin multiplexing tissue diagnostics business test three diabetes care devices accuchek nano smartview discreet blood glucose selftesting accuchek microrna play important role almost tumours combo pumpmetre combination accuchek inform ii control expression oncogenic proteins influ professional glucose testing hospital rest ence treatment resistance whether cancer spreads world key launch cobas b system roche tissue diagnostics developed first fully auto used doctors office outpatient clinic help identify mated staining technique allow researchers detect manage patients metabolic disorders microrna proteins tumours microenvironment could help researchers better understand cancer develop new targeted therapies driving testing efficiency multiplexing technology allows simultaneous iden developing diagnostic platforms tests tification nine different targets mutated genes enhance testing efficiency clinical laboratories proteins single piece tissue means phy research centres number systems early sicians able get answers time initial latestage development including nextgeneration platforms diagnosis tumour still tissue available immunodiagnostic clinical chemistry coagulation test comparison case cancer return ing leading cobas series fully automated analysers designed help large labs consolidate also remain focused developing faster efficient work areas handle expanding testing volumes also sequencing systems nextgeneration sequencing allow developing cobas novel molecular scientists examine parts persons genome faster testing platform expected first offer new levels efficiently continuing collabora automation throughput costefficiency molecular tions external partners nextgeneration platforms blood screening laboratories also invested sequencing workflow enhancements initiated collaboration precision system science genome total genetic material organism comprising genes contained chromosomes oxford medical dictionary research development roche business report diabetes care pumps cgm late started guideit clinical trial investi gates benefit heart failure test ntprobnp ther roche continues develop innovative integrated diabe apy monitoring heart failure patients pivotal trial co tes management systems help patients caregivers ordinated duke clinical research institute main study optimise therapy focusing investments insulin funded us national institutes health well pumps continuous glucose monitoring cgm roche ntprobnpguided heart failure care expected see greatest market potential innovative differenti substantially reduce occurrence cardiovascular events ated products pipeline includes nextgeneration insu worsening heart failure hospitalisation death lin pumpblood glucose metre accuchek insight well compared current standards care see novel micropump following decision cancel micropumps pilot launch late devel oping product combined metre pump continue study new diabetes management approaches proven accuchek features also developing cgm based innovative devices abacus study investigated system provides real time continuous glucose monitor use accuchek aviva expert automatic bolus advi ing small sensor patients skin cgm sys sor functionality calculate appropriate insulin doses tem early development delivered promising results based regular blood glucose monitoring insulin depen first clinical studies dent patients study results first presented october revealed use bolus adviser improved ability reach glycemic targets supporting therapy adherence patient wellbeing without increase number hypo automated emulsion pcr instrument preparation glycemic events genomic samples improving r productivity providing medical value improving productivity r priority roche developing tests provide new answers areas working make r practices efficient order oncology virology metabolism one example develop medicines sustainable way reduce time cobas pikca mutation assay designed takes bring products market detect mutations pik phosphoinositide kinase pathway pathway mutated cancer patients one approach design trials ensure shorter develop plays significant role colorectal gastric ment times using biomarkers example able breast endometrial tumours select patients likely respond treat ments means run smarter trials test research use launched early likely successful also allows us reduce costs per ivd test predicting response specific cancer therapies trial per patient developed launch coming years also early development tests identify variations gene expression another initiative trials patients tp aims better inform pik pathway tumour tissue see companion patients doctors benefits participating diagnostics pages cmet apoe tau clinical trial also developed online recruiting tools make easier patients enrol delivering clinical evidence enrolment clinical trials increased programmes like tp able accelerate drug development also investing collaborating clinical trials instance cancer patients participated trials patient demonstrate medical value diagnostic products enrolment times could cut one year three five helping physicians better monitor treat patients suffer ing illnesses heart disease diabetes guiding evidencebased therapy using biomarker intensified treatment polymerase chain reaction automated bolus advisor control usability study roche business report research developmentyears currently required according national cancer stembancc partnership institute roche playing leading role stembancc exciting part efforts streamline r activities new academicindustry partnership help deepen took difficult decision close site nutley new understanding number complex diseases initiative jersey united states closure allow us allocate also improve drug development process resources expanding latestage pipeline focus promising agents stembancc project involves ten pharmaceutical companies academic institutions based nobel prize winning technology revolutionised way stem accessing external innovation cells used research approximately active partnerships molecules long time believed adult cells could divide third parties accounting around onethird roche make cells type example skin cells sales external innovation continues make valuable con make skin cells liver cells make tribution pipeline allows us broaden global liver cells innovation network recent years researchers developed way roche partnering signed new agreements includ reprogramming ordinary adult cells create stem cells ing three product transactions research tech used generate kind cell stem cells nology collaborations addition nine product outlicencing known induced pluripotent stem cells scientists agreements signed among teams main transactions john gurdon cambridge university shinya yamanaka exclusive partnership versant ventures kyoto university awarded nobel prize physiology inception sciences create drug discovery incubator medicine findings inception treatment sensorineural hearing loss deal structure particularly innovative involves advances mean take blood skin cell venture firm versant provides equity financing phar samples patients examine diseases petri maceutical company roche contributes funding dish technology also allow us test potential small resources research biotech firm inception molecules biologic treatments early stage provides innovative technology platform well drug discovery process drug hunting expertise inception sciences team project launched roche innovative genentech partnering signed new agreements medicines initiative end focus diabetes including three product transactions three research tech central nervous disorders including dementias autism nology collaborations four academic collaborations four schizophrenia well peripheral nervous system dis outlicencing agreements entered unique deal orders especially pain partnership run five years structure usbased constellation pharmaceuticals includes future option acquire constellation based pre roche scientists worked induced pluripotent stem negotiated terms major strategic agreement based cells partners harvard university massachusetts science epigenetics chromatin biology discover general hospital three years created develop treatments cancer serious diseases human induced pluripotent stem cell lines used model cardiovascular diseases recently also diagnostics division signed licensing agree joined forces boston childrens hospital harvard ments also made tender offer us group illu use stem cells model neurological diseases mina rejected research development roche business report conducting responsible r animals used research roche contract research organisations clinical trials mice rats clinical trials critical determining safety efficacy rodents rabbits new medicines clinical trials compliant good clinical practice guidelines international quality dogs standard information trials shared regu latory authorities payers regardless outcome primates trial roche dedicated providing balanced information trial healthcare professionals public perform trials countries intend market med icine tested patients involved clinical trials bioethics roche published several position papers r activ clinical trials ities areas genetics stem cells animal research routinely review update positions pol icies research involving either humans animals taking number clinical trials account scientific developments public concerns number healthcare centres involved roche charter genetics ensures genetic number patients research meets highest standards socially responsi phase iiv clinical trials ble believe right every individual selfdetermi nation privacy confidentiality regarding collection excludes noninterventionist screening programme use genetic information details clinical trials available wwwrochetrials animal welfare com wwwclinicaltrialsgov international fed take public concern animal research seriously eration pharmaceutical manufacturers associations throughout worked maintain already high clinical trials portal us national institutes health standards animal welfare wherever possible seek alter global registry natives use animals computer simulation vitro testing using differentiated cells stem cells without roche encourages scientists publish results work putting risk reliability validity research test medical journals present scientific medi results follow rs approach cal congresses scientific articles reduce number animals needed roche scientists published leading journals refine tailoring procedures minimise pain dis nature cell science new england journal medicine comfort replace methods involve animals use cells tissues animals ethical practices animal research remains indispensable biomedical research roche science ethics advisory group seag scientific legal reasons regulatory authorities require made independent external experts bioethics phi healthcare companies test safety efficacy new losophy offers advice counsel broad range drugs animals used humans ethical matters including ethical approaches biomedical clinical research seag follows consultative approach used animals research topics perceived particularly sensitive controver decrease number animals used contract sial public large order take account many research organisations working roches behalf decreased perspectives possible compared approximately roche business report research developmentof animals used mice rats overall decrease animal usage direct reflection restructuring roche organisation drug portfolio changes web roches pharmaceuticals diagnostics pipelines wwwrochecompipeline personalised healthcare wwwrochecompersonalisedhealthcare group policies positions guidelines wwwrochecomresponsibilitysustainability positionspoliciesdownloadshtmguidelines clincal trials safety wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety new products technologies wwwrochecom innovationandtechnologies ethical standards wwwrochecomehticalstandards httpwwwrochecomaboutrochecorporategovernance codeofconducthtm genetics bioethics wwwrochecomgeneticsandbioethics animal welfare wwwrochecomanimalwelfare research development roche business report pharmaceuticals pipeline noitacidni tcudorptcejorp di tcejorp sromut meh dilos tna mdm gr sromut dilos bam reh gr sromut dilos bam rfsc gr sromut dilos hni kemfic gr amonalem tem bamumilipi faroblez gr ygolocno bam kaewt gr ygolocno bam fgevgna gr sromut dilos hni laud kem far gr sromut dilos bam dc gr sromut meh dilos tna mdm gr sromut dilos hni kem gr sromut dilos rotibihni tka gr sromut dilos bam ldp gr ac etatsorp cda paets gr ac nairavo cda gr amoleym elpitlum cda gr ygolocno cda gr ygolocno cda gr lhn dna llc hni lcb gr amohpmyl mut dilos hni khc gr sromut dilos hni kip gr amonalem citatsatem cda gr l amotsalboilg hni kip gr sromut dilos hni khc gr clcsn rotibihni kla gr sromut dilos hni kip uhc eniccav recnac editpep tw uhc enil dn cbm reh atejrep gr recnac cirtsag reh atejrep gr cb ylrae reh mdt gr recnac cirtsagreh mdt gr ccb elbarepo egdevire gr llenil dnts cbm genelpirt bamuzutrano gr l enil ts crcm bamuzutrano gr l ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr enil dn amotsalboilg bamuzutrano gr sromut dilos bam rfge gr recnac dioryht yrallipap faroblez gr sromut dilos hni kip gr sromut meh dilos hni rotmkip gr sromut dilos bam lfge gr sromut meh cda dc gr sromut meh cda bdc gr sromut lailehtipe rfgereh gr recnac revil bam nacipylg gr jda cb reh nitsava gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksir hgih nitsava gr enil ts amotsalboilg nitsava gr enil ts recnac nairavo nitsava gr tsiser munitalp recnac nairavo nitsava gr cb ylrae reh atejrep gr jda clcsn avecrat gr enil dr cbm reh mdt gr enil ts cbm reh mdt gr enil drdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr llc bamuzutunibo gr despaler lhn tnedicni bamuzutunibo gr lcbld bamuzutunibo gr eniltnorf lhn tnelodni bamuzutunibo gr jda amonalem faroblez gr amonalem faroblez obmoc hni kem gr noitalumrof cs lhn arehtbam gr lmt crcm nitsava gr mrof cs cb reh nitpecreh gr enil ts cbm reh atejrep gr enil ts tum rfge clcsn avecrat gr cbm detaerterp reh mdt gr ccb decnavda egdevire gr sesaesid enummiotua bam li gr ar bam li uhc sititamred cipota mic uhc sisorelcs cimetsys armetca gr sitiloc evitareclu bamuzilorte gr mehtyre supul cimetsys bamuzilatnor gr amhtsa bam emirp bamuziliuq gr ar ylrae armetca gr amhtsa ereves bamuzikirbel gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc apmapg arehtbam gr noitalumrof cs ar armetca gr aij ralucitraylop armetca gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr vch rivubortes gr setebaid epyt oga laud plgpig gr dvcsca bam nitceles p bamucalcni gr sesaesid cilobatem bam kscp gr dt ni sca tsop der ksir vc razatilgela gr dterpdt ni dvc der ksir vc razatilgela gr setebaid epyt razatilgela gr setebaid epyt tlgs nizoflilgofot uhc sredrosid ngoc man arbag gr msitua gatna rotpecer v gr sremiehzla hni ecab gr ainerhpozihcs aedp gr sremiehzla bamurenetnag gr sremiehzla hni boam gr noisserped gatna rulgm gr redrosid evislupmoc evissesbo nitrepotib gr noisserped tnatsiser xt gatna rulgm gr sremiehzla bamuzenerc gr dsa msitua nefolcabra tss smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emordnys x eligarf nefolcabra tss emdovrdma viled tsus sitnecul gr yhporta cihpargoeg baf rotcafitna gr nrp gm dma sitnecul gr ailihpomeh eca uhc approved eu submitted us rgno roche genentech managed approved us submitted eu chu chugai managed submitted eu sst seaside therapeutics optin submitted us rg mabthera branded us ongoing evaluation rituxan us japan fda submission rg actemra branded personalised healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelated macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nsclc nonsmall cell lung cancer cll chronic lymphocytic leukemia nhl nonhodgkins lymphoma cmv cytomegalovirus ppms primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rms relapsing multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabetes hcv hepatitis c virus ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac lartnec suovren metsys ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceuticals pipeline pharmaceuticals pipeline roche business report pipelineengfusszeilenindd ddnigneenilepipdrraehcorpharmaceuticals pipeline noitacidni tcudorptcejorp di tcejorp sromut meh dilos tna mdm gr sromut dilos bam reh gr sromut dilos bam rfsc gr sromut dilos hni kemfic gr amonalem tem bamumilipi faroblez gr ygolocno bam kaewt gr ygolocno bam fgevgna gr sromut dilos hni laud kem far gr sromut dilos bam dc gr sromut meh dilos tna mdm gr sromut dilos hni kem gr sromut dilos rotibihni tka gr sromut dilos bam ldp gr ac etatsorp cda paets gr ac nairavo cda gr amoleym elpitlum cda gr ygolocno cda gr ygolocno cda gr lhn dna llc hni lcb gr amohpmyl mut dilos hni khc gr sromut dilos hni kip gr amonalem citatsatem cda gr l amotsalboilg hni kip gr sromut dilos hni khc gr clcsn rotibihni kla gr sromut dilos hni kip uhc eniccav recnac editpep tw uhc enil dn cbm reh atejrep gr recnac cirtsag reh atejrep gr cb ylrae reh mdt gr recnac cirtsagreh mdt gr ccb elbarepo egdevire gr llenil dnts cbm genelpirt bamuzutrano gr l enil ts crcm bamuzutrano gr l ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr enil dn amotsalboilg bamuzutrano gr sromut dilos bam rfge gr recnac dioryht yrallipap faroblez gr sromut dilos hni kip gr sromut meh dilos hni rotmkip gr sromut dilos bam lfge gr sromut meh cda dc gr sromut meh cda bdc gr sromut lailehtipe rfgereh gr recnac revil bam nacipylg gr jda cb reh nitsava gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksir hgih nitsava gr enil ts amotsalboilg nitsava gr enil ts recnac nairavo nitsava gr tsiser munitalp recnac nairavo nitsava gr cb ylrae reh atejrep gr jda clcsn avecrat gr enil dr cbm reh mdt gr enil ts cbm reh mdt gr enil drdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr llc bamuzutunibo gr despaler lhn tnedicni bamuzutunibo gr lcbld bamuzutunibo gr eniltnorf lhn tnelodni bamuzutunibo gr jda amonalem faroblez gr amonalem faroblez obmoc hni kem gr noitalumrof cs lhn arehtbam gr lmt crcm nitsava gr mrof cs cb reh nitpecreh gr enil ts cbm reh atejrep gr enil ts tum rfge clcsn avecrat gr cbm detaerterp reh mdt gr ccb decnavda egdevire gr sesaesid enummiotua bam li gr ar bam li uhc sititamred cipota mic uhc sisorelcs cimetsys armetca gr sitiloc evitareclu bamuzilorte gr mehtyre supul cimetsys bamuzilatnor gr amhtsa bam emirp bamuziliuq gr ar ylrae armetca gr amhtsa ereves bamuzikirbel gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc apmapg arehtbam gr noitalumrof cs ar armetca gr aij ralucitraylop armetca gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr vch rivubortes gr setebaid epyt oga laud plgpig gr dvcsca bam nitceles p bamucalcni gr sesaesid cilobatem bam kscp gr dt ni sca tsop der ksir vc razatilgela gr dterpdt ni dvc der ksir vc razatilgela gr setebaid epyt razatilgela gr setebaid epyt tlgs nizoflilgofot uhc sredrosid ngoc man arbag gr msitua gatna rotpecer v gr sremiehzla hni ecab gr ainerhpozihcs aedp gr sremiehzla bamurenetnag gr sremiehzla hni boam gr noisserped gatna rulgm gr redrosid evislupmoc evissesbo nitrepotib gr noisserped tnatsiser xt gatna rulgm gr sremiehzla bamuzenerc gr dsa msitua nefolcabra tss smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emordnys x eligarf nefolcabra tss emdovrdma viled tsus sitnecul gr yhporta cihpargoeg baf rotcafitna gr nrp gm dma sitnecul gr ailihpomeh eca uhc approved eu submitted us rgno roche genentech managed approved us submitted eu chu chugai managed submitted eu sst seaside therapeutics optin submitted us rg mabthera branded us ongoing evaluation rituxan us japan fda submission rg actemra branded personalised healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelated macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nsclc nonsmall cell lung cancer cll chronic lymphocytic leukemia nhl nonhodgkins lymphoma cmv cytomegalovirus ppms primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rms relapsing multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabetes hcv hepatitis c virus ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac lartnec suovren metsys ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceuticals pipeline pharmaceuticals pipeline roche business report pipelineengfusszeilenindd ddnigneenilepipdrraehcorpharmaceuticals division major clinical trials product indication trial phase outcome actemra rheumatoid arthritis ra adacta iv statistically significant greater improve roactemra ment signs symptoms measured mean change das ra patients treated actemra mono therapy vs adalimumab monotherapy actemra polyarticular juvenile idiopathic arthritis cherish iii sustained clinically meaningful improve roactemra ment actemra iv vs placebo actemra early rheumatoid arthritis function iii statistically significant greater improve roactemra ment signs symptoms ra greater radiographic progression inhibition actemra combination methotrexate vs methotrexate alone actemra rheumatoid arthritis summacta iii comparable efficacy actemra sc roactemra formulation vs intravenous formulation subcutaneous formulation actemra rheumatoid arthritis brevacta iii statistically significant greater improve roactemra ment signs symptoms ra subcutaneous actemra sc vs placebo formulation aleglitazar reduction major cardiovascular alenephro ii renal safety study average decrease renal function events patients type diabetes patients stage chronic kidney experienced acute disease type diabetes revers ible coronary syndrome mild stabilises time avastin metastatic colorectal cancer ml iii significantly extended os patients first received avastin plus standard chemo therapy initial treatment continued avastin different chemotherapy cancer progressed avastin platinumresistant ovarian cancer aurelia iii significantly improved pfs avastin glioblastoma avaglio iii significantly improved pfs avastin triplenegative adjuvant breast cancer beatrice iii demonstrate significant improve ment invasive diseasefree survival versus adjuvant chemotherapy alone dalcetrapib patients stable coronary heart daloutcomes iii lack clinically meaningful efficacy disease following acute coronary syndrome herceptin herpositive early breast cancer hera iii year herceptin confirmed standard care herceptin herpositive early breast cancer hannah iii comparable efficacy subcutaneous subcutaneous formulation versus intravenous formulation formulation mabthera treatmentnave patients follicular sabrina iii minimum drug concentration confirmed subcutaneous lymphoma noninferior versus iv administration formulation comparable safety antilymphoma efficacy versus iv perjeta herpositive metastatic breast cleopatra iii significantly improved pfs os cancer combination herceptin docetaxel l trastuzumab herpositive metastatic breast cancer emilia iii tdm versus lapatinib significantly improved pfs os emtansine l xeloda tdm roche business report research developmentpharmaceuticals division major regulatory filings product clinical data supporting filing indication dosage form country actemraroactemra cherish polyarticular jia us eu actemraroactemra adacta ra dmard ir hh eu actemraroactemra summacta brevacta dmard ir tnf ir us eu subcutaneous formulation musashi dmard ir japan avastin brain recurrent glioblastoma japan avastin gog icon ovarian cancer japan avastin ml metastatic colorectal cancer tml us herceptin hannah herpositive earlystage breast cancer eu subcutaneous formulation lucentis harbor amd mg prn us mabthera rave rituxvas granulomatosis polyangiitis gpa eu microscopic polyangiitis mpa two types anca associated vasculitis mabthera sabrina sparkthera sawyer nonhodgkins lymphoma eu subcutaneous formulation perjeta cleopatra herpositive metastatic recurrent eu japan breast cancer tarceva eurtac nonsmall cell lung cancer egfr l us japan tablet mg mg mg china trastuzumab emilia herpositive pretreated metastatic us eu emtansine breast cancer tdm research development roche business report pharmaceuticals division major regulatory approvals product clinical data supporting filing indication dosage form country actemra option toward lithe moderate severe rheumatoid arthritis us adults inadequate response one diseasemodifying antirheumatic drugs dmard avastin oceans recurrent platinumsensitive ovarian cancer eu switzerland avastin ml metastatic colorectal cancer tml eu erivedge erivance bccshhg advanced basal cell carcinoma us lucentis ride rise diabetic macular edema us rituxan rate nhl fast infusion us perjeta cleopatra herpositive metastatic breast cancer us switzerland patients l tamiflu wp casg acute uncomplicated influenza infants us two weeks age older zelboraf brim brim braf v mutationpositive inoperable eu metastatic melanoma roche business report research developmentroche companion diagnostics market late development disease area disease drug diagnostic test technology application infectious cmv valcyte cmv viral load pcr monitoring diseases hbv pegasys hbv viral load pcr monitoring antivirals hbv pegasys peginterferon hbsag levels immunoassay monitoring alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitoring alfab mercksp hcv mericitabine rg hcv viral load pcr monitoring hcv danoprevir rg hcv viral load pcr monitoring hiv antivirals hiv viral load pcr monitoring hiv abacavir glaxosmithkline hlab genotype pcr screening oncology breast cancer herceptin perjeta expression ihc ish selection gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapies breast cancer trastuzumab emtansine expression ihc ish selection tdm rg gene amplification cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutations pcr selection colon cancer panitumumab amgen kras mutations pcr selection gastric cancer herceptin expression ihc ish selection gene amplification lymphoma brentuximab vedotin cd expression ihc selection seattle genetics millenium melanoma zelboraf braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab met expression ihc selection metmab rg nsclc crizotinib pfizer alk ihc selection nsclc tg transgene muc expression ihc selection inflammation asthma lebrikizumab rg serum periostin immunoassay selection levels rheumatoid mabtherarituxan rf anticcp ab immunoassay selection arthritis central nervous alzheimers disease gantenerumab rg levels immunoassay selection system others osteoporosis bonvivaboniva bcrosslaps immunoassay monitoring bisphosphonates pnp levels transplantation cellcept mpa levels immunoassay monitoring projects pharmaceutical companies disclosed confidentiality reasons available markets selection patients eligible firstline treatment black type market grey type development monitoring monitoring patients response particular treatment screening screening patients particular genetic variation hla associated hypersensitivity abacavir selection selection patients eligible particular treatment alk anaplastic lymphoma kinase anticcp antibodies cyclic citrullinated peptide braf bisoform rapidly growing fibrosarcoma oncogene cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis b virus hbsag hbv surface antigen hcv hepatitis c virus human epidermal growth factor receptor hiv human immunodeficiency virus hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogenes mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide rf rheumatoid factor sp schering plough research development roche business report diagnostics division major product launches area product name description market quarter instrumentsdevices laboratories benchmark special stains fully automated tissue stainer ww q ventana iscan ht scanner enables digital viewing tissue slides eu us q cobas p preanalytical system decapping sorting archiving eu us q cobas p preanalytical molecular testing system us q cobas middleware software control lab workflow test result eu q solution point care cobas b blood gas analyser critical care us q cobas b analyser hbac lipid monitoring eu q accuchek inform ii wireless system professional glucose testing us q hospital diabetes accuchek nano small nocode blood glucose metre us q care smartview accuchek mobile nextgeneration stripfree blood glucose metre eu q japan accuchek combo insulin pumpblood glucose metre combination us q life sciences lightcycler system realtime pcr analysis ww q seqcap ez products nextgeneration sequencing prepare enriched regions ww q genome seqcap ez oncology neurology panels new exome products gs flx software v enables improved longread sequencing performance ww q gs flx system cedex bio ht highthroughput analyser metabolite testing cell ww q fermentation biopharmaceutical production complete ultra protease inhibitor tablets use molecular biology research ww q mycotool realtime pcr analysis kit detection mycoplasma ww q testsassays oncology immunoassay early ovarian cancer detection us q p histology ihc tissue test early detection cervical disease ww q alk ihc tissue test identify patients eligible lung cancer eu q treatment crizotinib ihc tissue tests detection proteins tissue samples including ttf eu us q lung thyroid cancer hent various cancers ish tissue probes detection genes tissue samples including egfr ww q myc fgfr chromosome ki pr image analysis applications antigens ki pr p us q p algorithms support breast cancer diagnosis tissue samples gs gtype tetcbl gene sequencing primer sets leukemia research ww q kras runx infectious hcv ii immunoassay detect hepatitis c infections eu q diseases hbc igm immunoassay detect hepatitis b infections us q ctng pcr test detect chlamydia gonorrhoea infections us q hiv v pcr dualtarget test measure hiv viral load us q cmv pcr test monitor cytomegalovirus infections us q metabolism accuchek aviva require users insert code chip metre ww q performa universally ongoing calibration subsequent test strips coded test strips vitamin immunoassay measures vitamins us q roche business report research developmentdiagnostics division key product launches planned area product name description market instrumentsdevices laboratories cobas nextgeneration modular preanalytics eu diabetes accuchek insight nextgeneration insulin pump blood glucose metre eu care accuchek active nextgeneration blood glucose metre maltoseindependent test strips eu life sciences gs flx long amplicons software longread targeted sequencing dna variant detection ww testsassays oncology calcitonin immunoassay supports medullary thyroid cancer diagnosis monitoring eu progrp immunoassay assists diagnosis small cell lung cancer eu egfr pcr test supports therapy selection nonsmall cell lung cancer us er ihc tissue test breast cancer diagnosis us cintec plus cytology immunocytochemistry test diagnosis cervical precancer eu infectious mpx pcr nextgeneration blood screening multiplex test us diseases hiv hcv hbv hcv pcr nextgeneration hcv viral load test us trans cyclosporin immunoassays monitoring immunosuppressive drug therapy eu plantation tacrolimus sequencing seqcap ez reagent kits sample preparation targeted nextgeneration sequencing ww black type new productfirst market launch grey type new productlaunch additional markets eu european union us united states ww worldwide alk anaplastic lymphoma kinase cbl casitas bcell lymphoma gene ctng chlamydia trachomatisneisseria gonorrhoeae egfr epidermal growth factor receptor er estrogen receptor gs genome sequencer hbv hepatitis b virus hcv hepatitis c virus human epididymis secretory protein e hiv human immunodeficiency virus ihc immunohistochemistry ish situ hybridisation kras member ras family oncogenes p protein pinka pcr polymerase chain reaction progrp progastrinreleasing peptide runx runtrelated transcription factor tet member tet family oncogenes research development roche business report value innovation actemraroactemra relief agony childhood arthritis arthritis disease elderly rare form systemic juvenile idiopathic arthritis sjia one severe systemic inflammatory diseases childhood sjia affects children children sjia little energy fever enlarged liver spleen despite conventional therapies significant number children also face serious lifethreatening complications roches actemra breakthrough treatment first biological medicine approved sjia providing treatment debilitating condition making normal childhood possibility fatigue fever skin rash anemia inflammation around lung inflammation around heart enlarged liver spleen osteoporosis arthritis web httpwwwrochecomvalueofinnovation roactemra known actemra outside europe roche business report value innovation actemraenindd sport school activities friends fun playing laura gray diagnosed sjia seven years ago used particularly sporty person diagnosed part life completely taken table couldnt anymore due illness started missing quite bit school got behind lost friends couldnt keep sight mind awful lot wasnt drug im currently learning drive im going interview college option hadnt considered ill thought time thing way way table options opened actemraenindd manufacturing sites roche business report manufacturing procurement initiated million swiss franc investment diagnostics production penzberg germany enabled rapid launch new medicines perjeta erivedge available us patients one three days fda approval respectively developed new biotech production methods technologies including production processes first antibodydrug conjugate tdm roche business report manufacturing procurement key figures manufacturing sites pharmaceuticals diagnostics joint sites employees manufacturing logistics portfolio medicines tests instruments manufacturing procurement supply functions bring inno ceuticals network supported broad product portfolio vative medicines diagnostics r pipeline including new oncology treatments well added new patients healthcare professionals worldwide stages technologies overcame technical challenges biologics global supply chain suppliers manufacturers manufacturing diagnostics supported strong growth warehousing transportation require apply rigor sales clinical laboratories streamlined parts ous safety quality ethics labour health environmental network line business priorities standards stateoftheart processes facilities ensure standards fully met products made throughout networks maintained strong commitment available reliably quality compliance continued improve pro cesses develop new capabilities best serve product groups operations networks supported robust pipelines sites successfully passed regulatory sales growth new product development pharmaceu inspections resolved issues internal quality audits ticals diagnostics divisions enabling roche strengthen also continued reduce environmental footprint leadership oncology vitro diagnostics pharma implementing new logistics strategies capital investment basel kaiseraugst switzerland approx million swiss francs three projects completed maintained robust capital investment programmes new pharma quality control assurance building pharmaceutical diagnostics manufacturing net pharma coldchain storage capacity expansion works adding capacity improving production processes filling line upgrade herceptin subcutaneous roches leading engineering expertise recognised formu lation fifth consecutive year facility year category ongoing projects establish launch capacity highly winner operational excellence international society potent drug products upgrade filling line pharmaceutical engineering awards rocephin formulation throughout shanghai china approx million swiss francs investment highlights bud geted ongoing pharma site expansion including new penzberg germany approx million swiss francs laboratory warehouse office training facilities budgeted project initiated end completed additional manufacturing capacity expansion raw material manufacturing elecsys highly potent drug products expansion utility immunoassays completed end well infrastructure completed increase compounding filling lyophilisation capacity planned roche business report manufacturing procurementmanufacturing sites roche group mannheim kaiserb aua gse stl penzberg graz rotkreuz segrate clarecastle hillsboro vacaville south san francisco indianapolis brab nr ca hn bf uo rr gd legans utsunomiya oceanside tucson florence shanghai fujiedaukima toluca puerto rico singapore rio de janeiro biologics drug small molecules sterile drug solid dosage pharmaceuticals substances drug substances products drug products assays diagnostics instruments diabetes care reagents january pharmaceuticals manufacturing manufacturing sites play vital role every stage product lifecycle discovery commercialisation network reduce risk supply interruptions balance production pharmaceutical manufacturing network produces capacity dualregister manufacturing sites medicines commercial supply clinical trials allows us produce key pharmaceutical products worlds sophisticated biopharmaceuti one facility also outsource certain production con cal production plants network hosts approximately tract manufacturing organisations cmos gain additional global biologic production capacity making roche larg capacity increase manufacturing flexibility leverage special est manufacturer biotech sector ised technologies manage costs example part nered multiple cmos including manufacturer spe cialised biologics highly potent small molecules set processes facilities manufacturing trastuzumab worldwide mammalian cell culture capacity including cmos bioplan associates inc annual report internal analyses emtansine tdm antibodydrug conjugate manufacturing procurement roche business report manufacturing procurementenindd erivedge launch part roches emerging markets strategy work first class first patients local governments partners establish expand local production capacity increase access medicines monday january roche received see marketing distribution fda approval erivedge setting remarkable co ordinated effort roche team contract manu performance facturers active pharmaceutical ingredient primary objectives maintain supply reliabili ty sourced asia switzerland capsule produced product quality supporting pipeline development canada remained packaging shipment expediting launch new medicines roche artwork experts together printing company pharmaceutical manufacturing played decisive role worked around clock complete packaging design rapid launch us breast cancer medicine perjeta based final wording fda approval prepare available patients one day following fda approval actual packaging roche staff site skin cancer medicine erivedge distribution three days tuesday oversee packaging initial two lots approval collaboration r supported loaded afternoon separate trucks mitigate development projects new medicines including manufac damage delay wednesday morning new treatment turing investigational products approximately global safely warehousing distribution centre clinical trials involved tens thousands patients louisville kentucky us fda cleared shipment thursday erivedge way dis year took active steps safeguard operational tributors within hours reliability throughout organisation increased inventory safety stock levels ensure continuity product supply response unforeseen increases demand especially new product launches contributed total inventory increase division also increased oversight across supply chain including suppliers cmos ensure effective response case unexpected events new business continuity process manufacturing opera tions put effect biologics manufacturing antibodydrug conjugates biologics biotech manufacturing challenging process taking biotech next level involves living cells sensitive even slightest changes environment range factors striking new paths biotech manufacturing nutrient solution timing equipment used deter antibodydrug conjugates new class compounds mine yield amounts unwanted byproducts even antibody substances armed toxin structure active ingredient produced promising approach long considered difficult continued expanding biotech capabilities adding new put practice key challenge find right methods technologies one innovative approach composition chemical link antibody toxin antibodydrug conjugates adc antibody sub design scale production process stances armed toxin process steps biolog ensured stability expected safety profile medi ics adc manufacturing illustrated following cine required new processes new external partners new quality specifications added complexity already complex biotech production process successful inherently complex production process occasionally efforts manufacturing organisation collaboration present challenges unprecedented biopharma r resulted technical dossier filing ceutical industry included onetime detection roches first antibodydrug conjugate tdm eu bacterium leptospira earlystage production us mid also laid ground manufac cer drug mabtherarituxan importantly investigation turability medicines new class pipeline issue cooperation health authorities excluded possibility clinically relevant risk patients sur roche business report manufacturing procurementbiologics manufacturing process antibody small molecule nutrient solution oxygen fermentation sterile process temperature controlled logistics b cell line culture fermentation specific human genes inserted bac production cells removed cell culture transferred progres terial mammalian cells create unique master cell bank cultured liquid growth sively larger bioreactors special nutrient master cell line yields target anti medium transferred larger vessels medium added unique composition body biologics drug substance mas cells multiply optimised cell line enables pro ter cell bank frozen storage duction desired antibody apurification bconjugation formulation filling packaging antibody separated biomass additional steps antibodydrug conju drug substance formulated sta cells culture medium waste products gates antibody combined ble dosage form sterile liquid powder leading pure solution centrifu highly potent small molecule puri filled vials syringes packed gation purification concentration steps fied concentrated shipping specific desired antibody faced new potential manufacturing risk groundbreaking diagnostics manufacturing work shared within industry also experienced slower expected cell growth newly scaledup pro network duction process breast cancer treatment perjeta roche diagnostics manufacturing network handles team ran successful production campaign enabled aspects production well procurement logistics timely launch committing postmarketing production industryleading ivd product portfolio includes data reviews fda demonstrate resolution different stateoftheart instruments perform problem maintain future supply tests requiring reagent kits agent control components consumables pipettes cuvettes manufacturing procurement roche business report biotechenindd bits steel materials analytical services penzberg germany plastic juices new closed site burgdorf switzerland dna testing system additionally modified manufacturing network based changes product portfolio two diagnostics roches new midhighvolume testing platform cobas businesses closed roche applied science reykjavik expected first bring exceptional iceland site transferring production sequence capture levels automation throughput costefficiency devices madison us also initiated projects molecular testing blood screening labs also adds streamline diabetes care operations reduce costs considerable complexity development manufacture business unit adapts tough market environment get blueprint pilot production roche production throughout continued pursue several longterm teams backgrounds biology biochemistry engi initiatives aimed sustainable high performance neering started march set process established continuous improvement culture met transforming steel plastic software juices new rics manufacturing quality performance right first time system including variety test kits closely coordinated put methodologies tools place ensure effort included three manufacturing sites rotkreuz switzer robust production processes design quality manu land branchburg us penzberg germany r facturability first positive trends site pleasanton us multiple global external suppliers continued optimise manufacturing capacity asset manage complexity team worked ensure management initiated major capital investment pro exacting quality controls built production pro ject site penzberg germany see cesses highest quality standards applied inter started two new initiatives expected generate nally supplier sites significant savings next years supply chain excel lence initiative enhance reliable costeffective december first pilot molecular analysers supply products optimise inventory levels delivered customers field testing procurement excellence initiative ensure strategic sourcing improved supplier management including new supplier performance measurement tool manufacture majority instruments tests house allows us maintain cost quality advantages quality compliance leverage proprietary technologies special expertise however use external manufacturers access unique overriding goal ensure every person receives technologies control costs production safe medicines reliable diagnostic test results achieve handheld blood glucose metres large work stations consum apply rigorous standards wherever roche ables increasing number subassemblies product manufactured sourced moreover ensure quality management systems conform laws performance regulations well recent norms standards achieved goals saving costs maintaining including cgmp ich iso supply products meet divisions abovemarket sales growth example delivered nine million test harmonising enhancing quality systems kits roches elecsys immunoassay product line highly roche continued global harmonisation quality automated blood testing laboratories worldwide alltime management systems pharmaceuticals division high level output major achievement business established new system global standards also supported launch major diagnostic products areas quality management risk management key markets see table preventive corrective actions local implementation continued transforming network line business priorities operational excellence programme current good manufacturing practices cgmp international confe launched late consolidated chemical raw rence harmonisation technical requirements registration pharmaceuticals human use ich international organization standardization iso roche business report manufacturing procurementongoing diagnostics divisions efforts harmonise green warehousing multiple quality systems complete yearend harmonisation expected drive compliance end pharma warehouse mannheim efficiency instance enhancing manufacturing germany refrigerated normal storage externally organisations ability manage quality performance rated stateoftheart energy efficiency built exchange best practices across networks warehouse constantly optimised includes highly sophisticated environmentally friendly design fea assuring compliance tures processes example energy consumption regulatory authorities conducted safety quality minimised air conditioning heating system inspections roche groups sites pharmaceu oriented working hours window shutters reduce sunlight ticals sites diagnostics majority inspec radiation facility features heat tions resulted critical observations recovery system special gate insulation packaging waste recycled directly warehouse pallets collaboration authorities roche pharma resolved used greatly reducing waste drawing role model quality concerns regarding mircera xenical production striving kind energy efficiency discovered internal audit interrupted warehouses roche developed best practice action supply products held release catalogue rolled globally roche diagnostics continued track proposed revision vitro diagnostic directive eu well pre paring new fda rule unique device identification reducing environmental impact standardised coding devices plan implement new green logistics area increasing focus within supply packaging design barcodes warehousing procedures chains seek systematically reduce air emissions accordance final rule energy consumption waste contributed groupwide efforts reduce environmental impact collaborating health authorities reducing use airfreight implementing six seafreight roche continues collaborate authorities provide lanes supply hubs germany us saudi arabia expertise including input guidance documents south africa singapore hong kong israel france proposed regulations laws taking leading role change resulted reduction co emissions implementing quality design approach includes approximately tonnes strong focus risk management maximising quality performance design production processes perjeta additionally addressed energy consumption waste represented first fda submission industry bio warehouses reusing recycling packaging materials technologically manufactured drug based principles establishing goals calculate monitor achieve ments well fostering employee engagement increasing also partner choice industry input medi awareness training including example implementing cines companion diagnostics cdx work directly new elearning tool september fda shaping regulatory landscape cdx roche instance participated meetings information please see safety security health fda regulators cdx environment following supply chain management commitment quality innovation sustainability extends throughout supply chain responding quickly market developments ensuring reliable product sup plies reducing environmental footprint maintain highly integrated responsive global supply chains divisions manufacturing procurement roche business report procurement sustainability principles supplier code conduct incorporates principles pharmaceutical supply chain procurement teams work closely business units along initiative psci value chain seeking innovative purchasing solutions help achieve goals generate cost savings aligning building capabilities reinvested business create maximum value apply implemented new common standard measure total cost ownership concept holistic longterm report procurement savings continued drive major view benefits costs purchasing decision joint sourcing projects research studies temporary labour production related purchases credit cards busi procurement organised division procurement poli ness travel pursuing globally aligned approach cies processes systems along largevolume spend retains local execution realised substantial savings risk management closely aligned across group line business targets also negotiated key contract objective ensure sustainable performance adher google provide employees worldwide new uni ence best practice industry codes roche example form cloudbased email calendar expected requires suppliers commit activities enhance connectivity collaboration procurement along value chain supporting diverse needs right supplier partnerships procurement strategic partnering along value chain research development manufacturing commercial needs lab equipment raw materials reliable suppliers logistics service marketing services services invent develop providers high quality product successful launch new drugs diagnostics including supply patients customers commerciali sation products services run clinical trials lifecycle exam supplier diversity access medicines making events ples key partnerships small diverse contracting indian manu new approach managing con supplier owned businesses local facturer local filling packaging gresses meetings events partner communities specific rd supplies herceptin mabthera greater transparency partici ships improve access medicines pation prioritisation events initiatives value outsourcing india involves transfer significant tools planning booking development new contracting process knowhow enabled substantial cost savings model outsource entire clinical programmes external partners roche business report manufacturing procurement procurementenindd expect generate value efficiencies audit protocol ten suppliers audited continuing enhance organisational structures capa protocol independent auditors bilities emerging markets enable proactive systematic management local spending example majority suppliers audited either met exceeded roche diagnostics started procurement office singa minimum requirements however decided stop business pore beginning support asiapacific one supplier meet minimum standards region roche pharma rolled nextgeneration pro main findings direct spend area related industrial curement system china hygiene safety design findings service providers enhancing relationship management oversight sup occurred primarily social ethics areas pliers new procurement excellence programme diagnostics frame pharmaceuticals focus supply reliability web developing people exchanging knowledge new global learning development platform biotech production wwwrochecombiotechnologyproduction pharmaceutical supply chain initiative pharma procurement catalogue customisable wwwpharmaceuticalsupplychainorg courses access internal external resources supplier engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecom rochesuppliercodeofconductpdf procurement along value chain engaging suppliers seek build mutually beneficial sustainable relation supporting diverse needs right supplier partnerships ships suppliers actively engage collaborate manage performance risk ensure quality compliance reduce combined environmental footprint promote innovation thereby take account different business needs along value chain see illustration june roche launched industrys first supplier rela tionship centre south san francisco us roche employees colocated representatives five key sup pliers dedicated find innovative ways generate mutual benefits also rolled new elearning module help suppliers increase knowledge among employ procurement strategic partnering along value chain ees sustainability roche supplier code conduct industry standards supplier day shanghai china research development manufacturing commercial around participants provided opportunity suppliers learn sustainability audits needs lab equipment raw materials reliable suppliers logistics service marketing services partnership institute supply chain management services invent develop providers high quality product successful launch diversity alliance science roche also engaged new drugs diagnostics including supply patients customers commerciali sation products programme provide opportunities innovative com services run clinical trials lifecycle petitive diverse suppliers exam supplier diversity access medicines making events monitoring compliance ples key partnerships small diverse contracting indian manu new approach managing con ensure compliance roche industry codes supplier owned businesses local facturer local filling packaging gresses meetings events standards conducted supplier audits across partner communities specific rd supplies herceptin mabthera greater transparency partici ships improve access medicines pation prioritisation events regions including five followup audits initiatives value outsourcing india involves transfer significant tools planning booking direct spend area goods go directly pro development new contracting process knowhow enabled substantial cost savings duction model outsource entire clinical service providers programmes external partners roche also collaborated healthcare companies psci developed unified joint sustainability manufacturing procurement roche business report procurementenindd value innovation chest pain approximately emergency room consul tations patients heart attack symptoms us alone million patients seen emergency departments every year chest pain rapid accurate diagnosis early risk assess ment critical patient arrives troponin test high troponin heart attack likely initiate treatment low troponin consider rule heart attack available us st twostage testing diagnose nd markets heart attack release patient also considering ecg information clinical hr hr hrs hrs hrs hrs hrs symptoms hospitals using highsensitive test time second test may new highsensitive test allows reducing time reduced hour second test hours ongoing clinical study taking cardiac testing next level studies ongoing enhance use medical value troponin testing clinical practice emergency setting well beyond instance regular checkup patients risk onehour diagnosis heart patient monitoring major attack study evaluating surgeries another study assesses whether chest pain patients use troponin test securely diagnosed one troponin high patient monitoring major noncardiac sur sensitive test admission final gery million adults worldwide undergo test one hour trial help patients major noncardiac surgery year take pressure emergency departments one million die within days regular troponin enabling rapid transfer specialised treatment testing help physicians identify patients early discharge trapidami study started risk detecting cardiac injuries might wise go unnoticed could cause death vision study started web httpwwwrochecomvalueofinnovation roche business report value innovation cardiacmarkersenindd highsensitivity cardiac test precise testing life death decisions diagnosing heart attack patients one challenging problems facing doctors hospital emergency departments heart attack requires immediate often serious intervention like heart catheterisation coronary bypass surgery blood test accurately determine whether patient heart attack literally mean difference life death twenty years ago physicians rely symptoms electrocardiograms ecg could miss heart attacks roche developed elecsys troponin highsensitive test detects presence troponin protein released blood stream heart attack troponin tests reliable indicators heart attack gold standard worldwide cardiac critical care heart attack blood flow blocked muscle cells dying troponin released heart attacks caused inter ruption blood supply parts heart causing heart cells die commonly due blockage coro nary artery following rupture substance called arterial plaque inner wall arteries prof christian mller cardiologist head outcome research university hospital basel highsensitivity cardiac troponin indispensable test early diagnosis heart attack enables us detect small heart attacks could missed use conventional tests also critical help allocation resources emergency department identify patients cardiac disease early focus right resources patients outset cardiacmarkersenindd patients received treatment one topselling roche medicines roche business report marketing distribution customised innovative market solutions increase access medicines launched educational initiative nine asian countries promote excellence testing herpositive breast cancer started programme peruvian government provide cancer care access million countrys poorest citizens roche business report marketing distribution key figures core marketing distribution expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sales diagnostics millions chf cer sales constant exchange rates average fullyear employees roche group pharmaceuticals diagnostics tailored market strategies sustain medical innovation order meet medical need help address mounting pressure healthcare budgets healthcare systems around world vary greatly regions sophisticated new medicines diagnostic priority diagnostics division support devel tests readily available others healthcare infra opment reimbursement programmes identify estab structure limited even basic medical care luxury lish evidencebased payment coverage decisions access good medical care depends many different provide effective accurate assessments analytical factors including income levels availability medical profes clinical validity advanced molecular diagnostic tests sionals political commitment common health particular diagnostics division united states capi care authorities intense budget pressure need talising reimbursement programmes proven sustainable healthcare solutions pressure driving results market ever innovative ways bring effec tive medicines patients affordable cost another initiative roche heavily involved co founded green park collaborative international roche focus ensuring products demon group exploring feasibility developing guidelines strate real benefits patients well represent mean design clinical studies meet needs hta organisa ingful expenditure healthcare authorities wherever tions payers aim programme involve may increasingly developing ways bring value payers earlier improve relevance clinical research healthcare systems enable many people possible accelerate patient access new drugs technologies benefit medicines also actively participating joint initiative demonstrating value pharmaceutical industry santsuisse association work closely healthcare authorities insurers swiss health insurers stakeholders develop basic payers demonstrate value products services principles future htas switzerland established turn gain appropriate reimbursement market consensus valuation health technologies access collaborate various authorities policy objective improving quality transparency health makers actively contribute health technology assess care system well increasing efficiency thus reducing ments htas systematically evaluate costs costs project triggered broad interest outside benefit innovative medicines diagnostics order switzerland example stakeholders typically guide efficient effective use aim conflicting interests come together roche business report marketing distributionaccess healthcare programme highlights children supported seven african countries india infants tested hiv amplicare initiative monitoring diabetes partnership novo nordisks changing diabetes children programme countries roche file enforce patents laboratory technicians trained hiv diagnostics medicines partnership us presidents emergency plan aids relief right solution right market system majority population turn situation view one size fit comes bringing different approach disparities work products market developing right solutions governments support public healthcare access individual market requires significant longterm commitment find solutions bring medicines need understanding needs challenges country piloting several differential pricing programmes partnership well healthcare system decentralised busi governmental organisations include providing ness model empowers local management teams work diagnostic tests education part packaged solution closely healthcare providers determine best appropriate individual country needs example customise solutions appropriate local market conditions south africa worked government enable mabthera treatment nonhodgkins lym phoma reimbursed public healthcare system innovative pricing models second brands part tailored approach local healthcare systems emerging markets also invested locally develop reimbursement arrangements around value rather partnerships manufacture finish products uniform pricing structure example pro order improve access medicines underserved grammes place differentiate price medical value market segments products commercialised drug vary depending indication different brand names come slightly different used treat also pay performance pay forms example vials rather syringes approach ment models example italy refunds given supports longterm growth strategy markets disease progressed earlier anticipated accord providing affordable solution public healthcare ing pivotal trial programmes models authorities successful number markets western europe example india roche emerging markets key roches growth strat developed second brands cancer drugs herceptin egy economic growth necessarily matched improve mabtherarituxan first step wider initiative ments healthcare infrastructure funding within implement manufacturing roche products collabora markets also striking differences access tion local partner stateoftheart facilities medical care higher income private sector people biologics manufacture second brand strategy drives access quality healthcare however public health growth india partnership government marketing distribution roche business report helping patients access increases access medicines patients poverty new medicines line another example second branding egypt launched second brand hepatitis c drug public focus enrolling patients clinical trials obtain healthcare market since people data required enable regulatory reimbursement treated might otherwise received authorities review decide whether new treatment medicines marketed reimbursed approval regulatory authorities way make medicines patient assistance programmes broadly available patients use supervision also recognise many patients even developed qualified healthcare professional doctor countries still afford treatment even insur ance may able pay treatment fully however recognise may possible covered individual insurance plans mitigate barrier patients might receive benefit new medicine healthcare roche provides patient assistance programmes enrol ongoing clinical trials possible assist underinsured uninsured clinical trials potential disease settings available hence access medicines united states genentech specific circumstances roche may provide patients access solutions helped underinsured preapproval access paa unapproved investiga uninsured patients access appropriate medicines tional medicines outside clinical trials process genentech access care foundation provides free medi approved regulatory authorities could cines patients uninsured meet specific expanded access program us set financial medical criteria preapproval safety study eu countries compassionate use china also launched patient assistance pro gramme herceptin breast cancer medicine whereby treatment costs reduced increase number people benefiting drug public healthcare system infrastructure development many areas world healthcare infrastructure rudi improving breast cancer mentary significant challenges exist improving diagnosis asia limited fiscal constraints basic level critical shortages medical professionals health roche launched sphere scientific partnership facilities low awareness causes symptoms testing excellence programme asiapacific prevention treatment disease even poor electricity educational initiative promote facilitate excellence supplies keep hospital equipment running help resolve testing breast cancer herpositive breast cancer issues roche collaborates local stakeholders particularly aggressive form cancer requires governments international health organisations support timely accurate diagnosis education development healthcare infrastructure well improve availability medicines provide diagnostic programme currently runs nine markets asia tests peru example roche began programme china korea taiwan hong kong indonesia philippines government provide cancer care access mil thailand vietnam malaysia alone lion poorest citizens providing diagnostics pricing plans laboratories pathologists surgeons medicines support education infrastructure technicians educated initiative development sphere aims increase accuracy reliability algeria roche supporting initiative bring breast testing across asia turn increase chance cure cer screening women rural areas mammography disease programme also looks help centres far fully equipped truck spheretrained centres monitor improve testing locally referred mamobile trained nurses parameters well build first regional database radiologists travels mainly southern sahara give status breast gastric cancer mammograms local women programme also piloting biskra southeast country screen roche business report marketing distributionas many women day aim screening bespoke solutions many women eligible province possible chinese labs programme also rolled areas middle east roche diagnostics china since clinical labs business continuing grow times customer satisfaction rate chinese ivd market equipment sales track customer satisfaction regular intervals usually hospitals cities ivd business annually biannually benchmarking performance benefited considerable investment country peers industry averages surveys conducted well governments multibillion dollar investment roche third parties gauge customer satisfaction healthcare infrastructure representatives knowledge helpfulness visits effectiveness medical support clinical data dis ability offer broad range modular instruments tribution quality information educa desktop solutions largescale equipment key tional materials addition diagnostics division looks growth chinese customers primarily expand delivery times service technical support levels labs step step analyse feedback identify appropriate equally important broad array tests run communication channels establish sales marketing instruments including immunoassays plans setting targets areas identified represent fastestgrowing segment important customers see opportunities also developed flexible sales model distributors improve performance ensures distributors easier access instruments addition service team control pre post sales service ensure high customer satisfaction levels web together market strategy secured products wwwrochecomproducts market leading position growth diagnostics assessing value products pricing wwwrochecom medicalvaluepatentsandpricing china access healthcare overview wwwrochecom accesstohealthcare genentech access solutions wwwgenentechaccesssolutionscom list patient groups supported wwwrochecompatientgroups responsible marketing wwwrochecom businessintegrityandresponsiblemarketing roches policies guidelines positions wwwrochecom positionspoliciesdownloadshtm marketing distribution roche business report value innovation accurate diagnosis personalised healthcare focusing healthcare budgets targeted treatments rapid accurate diagnosis fundamental successful treatment cancer identifying patients likely benefit personalised treatment improves patient outcomes saves time money could better spent elsewhere breast cancer example cases aggressive type known herpositive treating kind breast cancer specifically hertargeted therapy patient increased risk cancer spreading general therapy may limited effect impact roche developed suite tests provide rapid reliable results enabling informed decisions hertargeted treatment patients dr alan sokolow former medical director us health insurance company accelushealth personalised healthcare dia gnostics two clear advantages significantly improve health also reduce healthcare costs would like see physicians adopting approach recognition payers realise new tests therapies deliver value offer quality less waste quality testing critical b ihc test dual ish test early step patients confronted breast marks proteins first line shows ratio genes cancer usually biopsy taking small amount testing chromosome secondline suspected tumour tissue analysing testing case equivocal ihc fully tap potential personalised healthcare test result key minimise risk false test results roches two tests shown inde pendent assessments accurate reliable automated processing sophi sticated tissue staining instruments helps save costs lab also reduces possibility human error ensures delivery patient results quickly possible literally overnight web httpwwwrochecomvalueofinnovation according nordiqc tests comparable superiority dual ish assay proven pathway antiherneu b roches b ihc test show loftin ir et al multisite clinical study rabbit monoclonal primary anti poor borderline results mayr et al showed reduces inaccuracy rate compared body leading competitive ihc assay produced competitive fish assay five false results ventana b test inform dual ish dna diagnosed patients correctly probe cocktail roche business report value innovation hertestenindd hernegative patients go different treatment course unnecessary therapy patients inaccurate test results may receive inappropriate treatment herpositive patients eligible treatment could dramatically improve chances survival cure resources saved costs test inaccurate test results jeopardise benefits resources optimally create unneccessary costs allocated hertestenindd swiss francs contributed patient organisations roche business report responsible business launched roche compliance pulse check evaluate progress noncompliance cases hosted think tank schizophrenia better understand needs patients carers worked regulatory authorities develop strong framework biosimilar approval roche business report responsible business key figures contributions healthcare institutions millions chf contributions patients organisations millions chf integrity sustainability aspects business roche also requires external business partners adhere one worlds largest healthcare companies roche high standards employees local managers maintains highest standards business ethics integ responsible monitoring reporting compliance well rity responding quickly noncompliant behaviour supplier code conduct clearly outlines expectations commitment responsible business behaviour goes suppliers chief compliance officer serves con beyond strict legal compliance demand conduct tact person external stakeholders issues relating ethical open forms basis sustainable implementation compliance roche group business creates longterm value stakeholders code conduct run business ways profitable roche tolerate violations code conduct responsible committed triple bottom line prin noncompliance allegation confirmed line managers ciple driving social environmental performance requested take immediate corrective measures diligence financial performance impose adequate sanctions employees warning sustainability management apply materiality framework letters bonus cuts termination employment contract continuously look positive impact sustain business partner behave appropriately ability initiatives could business hesitate terminate relationship employees report concerns either line man code conduct ager local compliance officer chief compliance officer alternatively report noncompliance issues roche group code conduct guides employees anonymously roche speakup line accessible business behaviour worldwide covering topics cor countries languages tolerate porate personal integrity social responsibility compli retaliation employees raised compliance ance management employees complete mandatory training concern good faith alleged violations code ensure understand code conduct including conduct reported via speakup line find help advice raise compliance concern business practices behaviour addition local compliance officers must report material business ethics incidents chief compliance officer roche developed compliance programme business ethics reports areas incorporates key elements good practice compliance fraud theft violation good marketing practices embezzle program clear purpose embed compliance ment false records conflict interest discrimination daytoday business operations convinced harassment allegation carefully investigated result compliance closely linked good leadership leaders ing termination employment contracts account obliged foster environment trust encourages unethical behaviour two agreements business employees speak measured business partners reason results ability manage teams roche business report responsible businesscompliance initiatives contributions healthcare institutions launched several supplementary initiatives includ total amount million swiss francs ing roche compliance pulse check setting healthcare compliance council hcc compliance pulse education check tool enable local management employees healthcare professionals compliance officers assess progress handling education detection noncompliance cases hcc headed general public chief compliance officer brings together compliance representatives pharmaceuticals diagnostics research divisions well compliance experts various regions affiliates hcc fulfils coordination function intended ensure common interpretation healthcare provi code conduct well industry countryspecific sions code conduct support consistent marketing codes guidelines best practices addition implementation roches compliance programme roche uses groupwide questionnaire help local manag group ers assess compliance awareness responsible sales marketing practices general managers sunshine act regulations must sign declaration assurance acknowledging strengthened good business practice compliance practices putting place new global webbased system process contributes roches ability comply new regula goal enable healthcare professionals make deci tory transparency requirements like us physician payment sions independently based relevant data available sunshine act well similar disclosure regulations delivering greatest medical benefit patients europe elsewhere world system enables roche collect contributions made healthcare professionals education healthcare professionals global functions crossborder engagements roche dedicated supporting education healthcare prepares roche fully compliant sunshine act professionals highest quality programmes regulations aim improving knowledge disease product areas particular expertise education whether doctors nurses healthcare officials care stakeholder engagement givers main objective ensure best care possible patients roche believe open constructive interaction patients healthcare professionals improves ability end broad range educational activities fit treatments patients publication education training materials hosting supporting medical congresses focus pharmaceutical industry governed strict regulations many different aspects medical care including new guidelines sale marketing products roche standing diseases different treatment options safety rigorous internal processes place ensure concerns product use healthcare general diagnos employees adhere laws regulations industry codes tics establish testing laboratories train lab technicians conduct support good marketing practices code run pathology educational courses set quality control conduct sets standards adhering regulatory programmes compliance interacting engaging healthcare professionals interactions healthcare professionals activities seek exchange scientific infor aimed exchanging scientific information best use mation knowledge roches products services interactions improve understanding emerging clinical data relating based standards integrity fair remuneration ser therapies investigation vices committed benchmarking achievements increase clinical provider payer understanding best practice includes transparent reporting best treatment options including safety efficacy vari ous therapies patients continuously train staff interact healthcare pro help clinicians communicate medical information effec fessionals increase awareness understanding tively patients caregivers responsible business roche business report patient support examples contributions patient organisations total amount million swiss francs wwwaccuchekconnectcom offers tools resources living diabetes well educational grants clinical evidence case studies healthcare professionals workshops seminars wwwbonivacom offers osteoporosis prevention meetings care patients using boniva myboniva program treatment adherence projects provides resources help compliance wwwherceptincom offers guidance disease awareness general education treated herceptin herpositive breast gas tric cancer information financial support among resources wwwcancerchampionprogramorg offers support advice cancer patients responsible use medicines also priority area us websites products mechanisms remind patients take medication well provide access trained nurses information live disease medical side effects education enhance patient care provide courses different formats digital additionally roche operates counselling centres tele classroom networkbased within hospital lab environment phone help lines coordinates services improve treatment part existing medical event example year compliance rehabilitation also actively engage organised symposiums virtual medical conferences patients patient groups gain insight challenges connected annual meeting american society facing patients families clinical oncology asco asco worlds largest clinical oncology event attracts thousands healthcare pro example hosted think tank schizophrenia fessionals also supported continuing medical patients caregivers europe idea learn education symposium clinical management patients issues challenges facing caregivers acute coronary syndrome type diabetes european well patients order shape planning strategy society cardiology congress recommendation eu policy makers roche new medicine bitopertin development address negative parallel kinds activities roche provides grants symptoms schizophrenia independent medical education education generally provided independent organisation commu transparency essential interactions patients nity hospital academic centre society association roche publicly declares patient group relationships example made available unrestricted educational describes activities rochecom acknowledge grant enable independent scientific presentation financial nonfinancial support recommended rheumatic disease european league rheuma european federation pharmaceutical industries asso tism eular congress ciations efpia patients caregivers patient groups healthcare education awareness important patient safety patients wellbeing proper medical diagnosis treatment mind produce newsletters magazines products must effective must safe publications aimed helping people make healthy throughout shelf life roche continuously monitors choices prevent disease increase general awareness safety drug time evaluated clinical studies diseases organise disease awareness campaigns withdrawal market association patient groups local hospitals con duct screening programmes like algeria breast drug safety committee responsible drug safety cancer see p governance proactively ensuring patient safety roche business report responsible businessour employees required immediately report issue supports authorities efforts actively pursue relating safety quality medicines quality prosecute counterfeiters distributors processes systems regularly audited internally inspected major regulatory authorities roche addition implemented internal anticounterfeit ing measures design packaging labelling pharmaceuticals proactive safety management plan products recommend buying prescriptiononly medicines supported qualified physician monitors overall exclusively trusted sources doctors authorised safety risk management plans place reviewed pharmacies approved regulatory authorities adverse events stored global database reviewed qualified physician roche participates industry governmental reported promptly appropriate regulatory authorities efforts safeguard medicine supply chain protect required link roche product evaluate patients example worked closely eu com whether benefits medicine still outweigh risks mission development falsified medicines directive also maintain strict product recall procedures ensure aims stop counterfeit medicines reaching patients withdraw products rapidly quality safety introducing harmonised paneuropean safety control problems arise measures including unique product identification numbers tamperevident packaging restrictions repackaging despite extensive safeguards end follow also strongly advocate measures increased public ing internal quality review roche identified unreport awareness counterfeits ed potential missed adverse events patient assistance program us immediately launched investigation support anticounterfeit organisations pharma notified health authorities january ceutical security institute international federation initiated comprehensive corrective action plan pharmaceutical manufacturers associations well european federation pharmaceutical industry associa addition routine inspection uk regulatory authority tions cooperate companies january february identified findings roches safety related processes roche fully cooperated roche acts immediately potential counterfeits health authorities clarifying observations found products brought attention including informing cases implemented corrective preventative health authorities respective country counter action agreement health authorities based roches feit found assessments date impact safety profiles products found european medicines internally draw number departments skills agency health authorities confirmed medi fight counterfeiting roche established roche anti cines remain authorised without changes treatment counterfeiting commission consists members advice patients healthcare professionals correc affected departments heavily involved coordina tive preventative action resulting inspections tion many anticounterfeiting activities also inves completed newly defined processes imple tigative staff shanghai china highrisk regions mented become routine practice latin america middle east counterfeits biosimilars counterfeit products often look identical authentic versions similar biological medicinal products biosimilars making difficult detect especially patients coun becoming reality markets unlike generics terfeit medicines cause serious illness even death chemically synthesised medicines complexity bio contain harmful ingredients deprive patients logical production process means copycat products proper treatment never identical original medicines present new set safety competitive challenges national health authorities customs police intergovernmen pharmaceutical industry tal agencies international organisations world health organization take primary responsibility view biosimilars must meet rigorous prevention control counterfeiting roche collaborates regulatory quality standards innovator original organisations help prevent counterfeiting biological medical product order ensure patient safety responsible business roche business report protecting patient safety biosimilars regulatory pathways biosimilar pathways biosimilar pathways development means product intended copy licensed risk crisis management mono clonal antibody must demonstrate similar quality non clinical properties clinical safety efficacy headto risk management policy sets approach identi head studies otherwise product described fying managing reporting internal external risks intended copy biologic monoclonal antibody also use stakeholder feedback help manage social environ biosimilar mental economic risks roche active support development strong using consistent methodologies processes routinely regulatory framework approval biosimilars perform risk assessments levels organisation engaged discussions primarily associations group risk report covers material risks annually emerging biopharmaceutical enterprises biotech discussed corporate executive committee nology industry association america international audit committee board directors regularly federation pharmaceutical manufacturers associa update risk management processes raise awareness tions clear guidelines implemented understanding risk throughout roche group fda european medicines agency world health organization well number key emerging markets group risk management team provides advisory services india south africa much latin america sites affiliates project product teams monitors risk patterns specialist areas social media security compliance sustainability elearning programmes class roche business report responsible businessroom training workshops place improve political donations standing risk help employees manage appropri ately roche remains independent political affiliation additionally established incident management teams switzerland roche spends around million swiss francs throughout roche group ensure act quickly contributions donations various organisations safe emergency teams regularly rehearse different crisis guard interests include payments interpharma scenarios alerts escalation procedures continue economiesuisse scienceindustries swissholdings various strengthen business continuity management bcm chambers commerce financial assistance trade unions ensure sites respond effectively catastrophic donations political parties cantonal federal events business continuity management task force level donations political parties lowdoubledigit established group bcm policy guideline together thousand franc sums overall less total contri templates facilitating consistent aligned local implemen butions donations tation groupwide rollout new bcm framework make sure roches operations resilient capable employees us make personal political contri absorbing important disruptions butions roches good government committee genentechs political action committee genenpac voluntary political action committees employees contributing public policy donated us dollars political campaigns committees roche actively engages consultation governments industry bodies regulatory authorities stakeholders issues affecting pharmaceutical medical device web industry objectives help develop laws regulations policies public health shape debate roche group code conduct wwwrochecomcodeofconduct roche supplier code conduct wwwrochecom areas priorities included working eu clini rochesuppliercodeofconductpdf cal trial regulation objective supporting harmo positions policies guidelines wwwrochecom positionspoliciesdownloadshtm nised streamlined framework clinical trials well roche position respecting human rights wwwrochecom facilitation multinational trials addition responsibilityemployeeshumanrightshtm risk management compliance wwwrochecom actively promoting discussion around issues parallel riskmanagementandcompliance trade reference pricing detrimental consequences responsible marketing wwwrochecom businessintegrityandresponsiblemarketing lowprice eu countries aim raise issue un list patient groups supported wwwrochecompatientgroups equal access highvalue medicines endorse princi roche clinical trials patient safety wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety ple differential pricing way enable better access counterfeiting wwwrochecomcounterfeiting pharmaceuticals citizens europe areas con patents biosimilars wwwrochecompatents stakeholder engagement wwwrochecomstakeholderengagement sultation eu included new rules medical devices ivds well data privacy personalised healthcare respecting human rights roche fully supports implements united nations ruggie framework protect respect remedy designed prevent address risk adverse impacts human rights linked business activities corporate sustainability committee assessed risks opportunities related roches business best implement un framework committee subsequently established roche position respecting human rights endorsed corporate executive committee use internal external communication responsible business roche business report value innovation working insurance industry china improving health insurance coverage cancer patients cancer major killer across world yet healthcare coverage cancer treatment many countries patchy cases nonexistent roche working private insurers clinics asia latin america europe help better serve cancer sufferers like many countries china facing sharp increase cancer rates cancer killer urban areas second leading cause death country whole ageing population pollution heavy smoking adoption western lifestyles mean cancer remain major health issue china foreseeable future currently cancer patients china pay cancer treatment sometimes even sell cover costs recent years roche started work closely insurance companies help establish insurance policies million policies covering cancer treatment costs sold china ryan bi taikang life insurance co ltd customers need diagnosed cancer following first way paying cancer treatment insurance money comes second treatment plan important area insurance company lack knowledge roche board exactly help need green channel access next step green chan nel access plan would offer benefits people insurance policy green channel access would allow insured get seen quicker relevant doctors would another key selling point insurers would also generate revenue hospitals roche bringing insurers hospitals together order achieve roche business report value innovation chinaenindd challenges support roche insurance industry national overview cancer treatment costs analysing treatment costs lack gathering help insurance companies data data difficult calculate risk pricing policies price policies sales forces fully recognise importance cancer coverage providing lectures cancer depth educating understanding insurance companies rolling cancer awareness always value understand campaigns benefit innovative treatment patient insurance companies sharing information always know knowledge guiding constitutes good clients get good cancer gaps cancer treatment treatment web httpwwwrochecomvalueofinnovation chinaenindd employees worldwide fulltime equivalents roche business report people established seven leadership commitments standard behaviour expected every roche leader introduced innovative employee benefit programmes support talent retention hosted diversity summit leaders address role leaders creating inclusive diverse workplace roche business report people key figures women key positions since track reach goal roche employees worldwide fulltime equivalentsfte employees fte function europe marketing distribution north america research development asia manufacturing logistics latin america servicing australia general administration africa total total employees fte operating unit employees contract type roche pharmaceuticals regular fte chugai fixed term fte diagnostics division full time headcount part time headcount total fulltime equivalent fte used reflect actual working time full parttime employees example two parttime employees working would result equivalent one fte versus two employees headcount people drive business dedication determination support systems encourage collaboration give people translate innovations science better people need develop personally profes lives patients enabled roche remain forefront sionally healthcare industry century embrace diversity cultures people across roche group recognise employees engaged key yet matter share three fundamental values delivering highest standards greatest levels integrity courage passion innovation one way track engagement use employee surveys first companywide survey roche group global employee opinion survey geos building great workplace conducted put employee engagement line industry average strategic goal however roche committed constantly strengthening maintain reach employee engagement level end ing excellent workplace one fosters innovation followup employee survey conducted early goes beyond offering attractive compensation benefits better understand journey excellent workplace critical success wellbeing people strive build work environments roche business report peoplein response geos employee feedback leadership commitments corporate executive committee cec established employee engagement taskforce included leadership believe every employee deserves great leader work stream gathered input therefore expect following every leader regardless roche leaders develop leadership commitments area work level responsibility commitments outline behaviour expected roche leaders serve common standard people lead every day strive lead example consistently demon ership levels across company strating roche values integrity courage passion rolled globally integrated key hr pro means cesses recruitment development performance take genuine interest people management additionally taskforce identified ways listen carefully tell truth explain improve visibility transparency employee career empower trust people make decisions development see learning development p discover develop potential people strive excellence extraordinary results taskforce also backed global programme recognise set priorities simplify work individuals timely meaningful ways contribution congratulate people job well done locally culturally tailored recognition awards ranging simple thank formal rewards pro gramme elements piloted south san francisco pharma development globally worldwide imple employer choice mentation broader programme anticipated roche consistently recognised globally employer choice reflecting commitment foster maintain also introduce global wellbeing programme collaborative working environment embodies roche builds aligns many existing local initiatives core values integrity courage passion table ensure employees around world access highlights awards earned roche wellbeing initiatives continue identify implement activities initiatives group local level address employee engagement key awards recognition switzerlands top employers ranked st crf institute roche pharma switzerland fortune best companies work th consecutive year genentech south san francisco science top employers ranked rd genentech south san francisco science top employers ranked th roche germanys top employers certified crf institute roche pharma germany total equality award winner total equality deutschland association roche diagnostics roche pharma germany chinas top employers certified one chinas top employers crf institute roche diagnostics shanghai limited denmarks best workplaces st place great place work institute roche denmark best employers slovakia ranked nd best employer study aonhewitt roche slovakia desired employers ranked th antal international roche pharma roche diagnostics poland universum ideal employers ranked nd top employer natural sciences roche switzerland universum ideal employers ranked th top employer natural sciences roche germany top great place work ranked st great place work institute roche brazil excluding genentech people roche business report roche talent pool uk flexible benefits include health insurance vacation days bought sold preparation job vacancies filled internally bike purchases personal fitness taleo recruitment platform rochehosted career websites countries drew million also attract best scientific talent collaborat visits compared million received ing directly academia postdoctoral pro applications posted vacancies registered grammes research early development gred new candidates database job seekers pred gred postdoctoral programme interested becoming roche employees positions whilst pred postdocs projects involved collaborations outstanding academic groups europe us switzerland china japan generally top employer pay close attention attracting retaining top talent changing needs expectations workforce actively promote flexible working models employees attracting retaining highly skilled passionate moti encourage use latest technology allow embed vated people helping perform consistently high roche mainstream culture levels vital ability innovate deliver superior business performance attracting employees staffing rates committed recruiting top talent increasing diversity workforce recognising sometimes new hires comes challenges marketplace include stiff internal staffing rate competition best people science medicine espe external staffing rate cially emerging markets india brazil china retaining employees turnover respond market conditions continuously adapt ing adopting innovative talent acquisition strategies reflect best practices using inhouse recruitment teams total talent scouts employ latest social media tools well europe retain traditional routes recruitment business north america schools universities connect engage talent asia ensure know opportunities available work latin america ing roche effectiveness efforts recog australia nised externally roche received potential africa park award best online talent communicator uk asia europe ranked second us online reasons leaving recruitment techniques emerging markets innovative approaches involve adapt employeeinitiated ing enhancing employee benefit programmes meet local employerinitiated market needs example neutral china turnover rates higher countries started phasein new flexible benefits include cancer insurance pharma employees families learning career development singapore programme includes elderly care nursing home expenses option called staycare employees encouraged expand expertise employees use flexible benefits fund pursue professional passions take ownership local family activities tickets cinema development supported managers museum continuous coaching feedback company provides roche business report peopletools resources support career development dialogues also introduced degree feedback tool leaders employees managers include online late launch globally starting tool assessments identify areas strengths development help leaders build understanding key strengths needs overviews key experiences required certain roles development gaps local career marketplaces help employees con sidering change role learn career options learning development significant element employee development philosophy focuses gaining experience personal growth job total training investment believe employees build greater skills capabilities million chf work global innovative company exposed training spend per employee new challenges cultures reason encourage chf employees pursue development opportunities may total number training hours consist broader role challenging project temporary million international assignment average training hours per employee working increase use stretch assignments number post graduate international moves develop employees encourage students interns people particularly women take international assignments excluding chugai offer extensive relocation support helping families settle spouses continue careers succession management overall number international assignments risen maintain specific succession plans top sharply recent years pri key positions corporate operating group level marily result expansion emerging markets monitor continuously ensure broad continuing globalisation organisation percent deep talent pipeline special skill set broad age women among employees international assign experience required also identified external ment increased pipeline talent addition onthejob development employees roche strength internal talent pipeline continued grow provides formal development opportunities mentoring example two key corporate executive committee coaching programmes large roche affiliates sites positions filled internally broader organisation training curriculum available across broad range positions identified succession skills emerging markets making significant invest planning continue make strategic priority ments employee development organisations roche china academy cemai training center provide formal technical sales leadership train embracing diversity ing employees regions believe diverse inclusive workforce provides maintain special focus development future inspiration innovation business depends leaders part groupwide talent management including embrace diversity fostering inclusive environment full suite development programmes leaders every enables differing views skills experiences exchanged stage career introduced programme freely openly top executives catalyst focuses leading change reinforces leadership commitments today employees women worldwide global programmes supplemented divisional regional employees represent different nationalities programmes leadership development forums global headquarters basel alone participants test leadership skills simulated real different nationalities life challenges intense threeday programmes include senior leaders observe assess participants strengths point areas improvement people roche business report diversity summit leaders example pharmaceuticals north america held womens leadership summit launched gwise genen one example roches many diversity initiatives included tech women science engineering network diag roche diversity leadership summit may nostics north america started women leadership brought leaders basel challenge perceptions network also hosted healthcare businesswomens address role leaders fostering diverse inclusive association european leadership conference basel workplace one day event included presentations headquarters conference featured panel diversity entrepreneurship women leadership flexible executives numerous healthcare organisations fos working cultural diversity thinking styles among tered networking among women leaders companies topics among attendees rated summit positively across europe would recommend colleagues roche networks several sites help foster diverse inclusive environment including basel open proud equal network launched encourage culture respect equality every one regardless sexual orientation basel family career networking group employees family responsibilities whether parents caregivers relatives support better worklife balance south san francisco african americans biotechnology south san francisco stages strengthening ties across generations additionally italy germany israel spain increased support employees introducing onsite child care holiday care children roche france established gender diversity remains among top priorities end charter diversity includes childcare flexible work number women top key positions went options equal opportunities commitment providing slightly compared previous year total num resources disabled charter also included plan ber high potentials identified indicates increased retain hire older employees consult working condi rigour highpotential process continued focus tions training skill development transition diversity expect continue making progress retirement roche turkey women represent remain track achieve overall gender goal employees top positions roche turkey increasing percentage women top key positions prestigious prism award efforts area international coaching federation leadership pipeline raised awareness throughout group diver sity one thing diversity inclusion grass roots campaign encourage people lead take part number highpotentials least one activity support diversity inclusion percentage women highpotentials gender diversity percentage women global leadership programmes women total workforce women line management support goal introduced several initiatives women top help women throughout careers range basic executive positions measures granting parental leave permitting flex women key positions ible work schedules enhancing mentoring sponsorship programmes maintaining ties leadership networks roche business report peoplereward recognition extended additional affiliates countries employees competitive compensation benefits programme one aspect roches strategy attract talented people moti vate retain current employees encourage strong fair employment practices performance company paid billion swiss francs remuneration employees treat employees fairly throughout employment cycle includes supporting affected organisa reward performance transparent consistent tional changes example consolidation streamlin process encourages fairness continuous feedback dia ing research activities pred resulted reduction logue development throughout also continued around positions transfer positions align remuneration policies processes across busi switzerland germany support impacted employ ness units established common tools language ees ensured comprehensive packages support employee performance appraisals help leaders give measures place including severance payment pro meaningful feedback encourage productive dialogue grammes outplacement services counselling access included use multirater tool employees onsite career lab retraining redeployment options resulted feedback requests sent september november alone activities included roche equal opportunity employer practice labs managers providing performance feed tolerate form workplace discrimination back ensure roche compensation performance management principles applied effectively consis roche employment policy governs human rights tently throughout group labour relations every roche site setting inclusive workplace philosophy exacting employment practices additionally added flexibility groupwide com chief compliance officer monitors implementation pensation portfolio empowering managers use annual compliance policy association hr managers bonuses longterm incentives acknowledge extraordi compliance officers roche site roche commit nary employee contributions ted enforcing policy sites using founda tion employment processes designed also agreed change longterm incentive programme monitored expects employees act accordance leaders maintain competitiveness compensa policy tion plans address feedback stronger alignment incentives share price performance revised plan updated policy implementation january takes effect underscores belief employee ownership enabling employees earn equity combination stocksettled stock appreciation rights respect employees right freedom association restricted stock units collective bargaining currently approximately employ ees trade union members belong labour groups additionally roche europe forum enabling hr excellence represents interests around employees countries recognise strong employee performance enabled aligned integrated processes systems finalised implementation common human web resource information solution chris serve foundation complete comprehensive services employees wwwrochecomemployees global careers portal careersrochecom manage employee information key human resources pro employment policy wwwrochecomemploymentpolicypdf cesses group policies positions guidelines wwwrochecompositionspoliciesdownloadshtm commitments employees wwwrochecomcommitments chris available ten languages roche legal entities health safety wwwrochecomenvironment employees operating countries january compensation performance modules chris people roche business report value innovation cobas hpv cintec tests better screening cervical cancer cervical cancer develops slowly years screening programmes based pap smear reduced number cervical cancer deaths many countries dramatically test foolproof many women missed pap test examines cells cervix abnormalities yet disease almost always caused persistent infection highrisk human papillomavirus hpv genotypes hpv infections harmless therefore important pinpoint infections likely cause cervical cancer roches cobas hpv test detects highrisk hpv identify women greatest risk developing cervical disease cintec products help better identify precancerous lesions enabling doctors remove unhealthy tissue cancer fully develop protect patients unnecessary treatment gives women peace mind safe receive appropriate care prevent cancer screening cervical cancer detected late symptoms usually meaning death sentence women risk cervical cancer virus cancer cobas hpv test detects cintec plus test detects highrisk virus types proteins associated genotypes particularly cancerous cell transforma hpv tion p ki incidence screening year new cases cervical cancer healthy hpv precancerous cervical tissue infection lesions invasive cancer succumb disease incidence highest developing countries lack screening programmes even developed regions highrisk hpv type root cause almost cases cervical cancer thousands women still die cancer infection hpv fairly common cases body able clear virus women however infection resolved cervical cancer prevention programmes persists lead cervical cancer relevant types predominantly based pap test hpv types considered high risk two types hpv vaccination modern hpv screening slowly responsible approximately cervical cancers adopted forerunners italy cobas hpv test provides individual test results hpv along introduced hpv primary screening several pooled result highrisk genotypes thus enables instant regions sweden intro identification women highest risk need immediate duced pilot programme stockholm intervention early test invented named us physician george papanicolaou roche business report value innovation hpvenindd christine baze cervical cancer survivor patient advocate years old diagnosed invasive cervical cancer despite fact going pap smears every year ten days later radical hysterectomy five weeks daily pelvic radiation four rounds chemotherapy three rounds internal radiation diagnosed pap work screening got better accurate addition hpv test pretty amazing think doctors patients get accurate information thing want women know take care bodies accurate screening possible screening based pap smears annual test misses around women precancers screening based molecular testing twostage approach identifies women precancers stage check cancers root cause hpv highrisk infections cobas hpv test stage check precancerous lesions web cintec plus test httpwwwrochecomvalueofinnovation hpvenindd employees participated roche childrens walk roche business report community involvement inaugurated second transnetphelophepa healthcare train bring primary healthcare remote regions south africa supported humanitarian social projects aftermath hurricane sandy partnered organisations philippines supply affordable solar powered lights people living shanty town tondo roche business report community involvement key figures breakdown giving area humanitarian social projects arts culture science education community environment since roche formed hundred years ago aim participate projects collaborator contrib company directed human financial resources com uting expertise resources earliest possible munity projects philanthropic initiatives make lasting stage sharing longterm risks commitments impact investments necessary achieve lasting benefits direct giving four areas priority humanitarian responsibility philanthropic activities delegated social projects science education arts culture local affiliates operating coun community environment matter size project tries selecting managing engagement locally cost focus outcomes philanthropic activities better tailor activities local priorities respond support engage must generate tangible longterm quickly urgent need arises benefits people communities measured innovation applying creative effective solutions activities guided roches global donations societys challenges noncommercial sponsorship policy philanthropic donations sustainability delivering enduring impact dynamic may made registered accredited independent resourceconstrained world nongovernmental organisations multilateral organisations collaboration drawing strengths skills notforprofit charities roche partnering organisation individually tailor activities needs project lighting philippines sunlight socalled solar bottle bulb powerful enough light small dark home plus environmentally friendly inexpensive easy make roche philippines employees entered partner ship myshelter foundation philippine christian foundation reduce dependence electricity open flame lighting people living tondo shanty town liter light project uses plastic soda bottles encased corrugated tin filled water bleach mounted roof allow light pass home solar bulbs take hour install get sunshine old plastic bottle filled last five years improve living environments water chlorine watt solar bulb refracts families also allow children read roche business report community involvementemployee involvement clinic rails phelophepa roche encourage employees involve described locals miracle train transnet communities work live means phelophepa healthcare train clinic rails brings give back engage personally enriching experiences primary healthcare remote regions south africa site site often support employee community service one doctor every residents offering flexible work schedules brokering volunteer assign ments coordinating group projects however refrain phelophepa means good clean health since launch exerting influence type amount volunteer roche main external sponsor work employees engage transnetphelophepa funding primary healthcare community outreach ancillary services part activities improve health worlds poorest countries offer secondment programme employees modest beginnings threecar train service enables contribute skills assignments expanded two coach trains humanitarian organisations least developed countries trains running weeks year phelophepa deliver medi well low lower middle income economies cal services healthcare education reach programme allows employees participate three twelve people annually including patients months project dedicated improving health need care train staff also visit schools providing vital roche secondees contributed projects india south africa health checks medicines education children haiti since employees united common cause roche childrens walk walkers roche sites around world participated oneday event raises money schools orphans malawi employees roche sites coun tries participated humanitarian social projects largest part philanthropic giving directed toward humanitarian social projects believe improving human services support systems effective way port european coalition positive people work help build stronger healthier communities malawi help children orphaned hivaids day centres skills training nutrition educational assistance preference provide support yielding outcomes maintained longterm basis local level aftermath hurricane sandy struck north example countries adequate healthcare east us october genentech foundation infrastructure trained healthcare workers hospitals neighbouring roche facilities new jersey quickly provided general health awareness find investments edu major donations american red cross shelter recov cation prevention usually sustainable solution ery assistance emergency transportation meals medicine diagnostic donations foundation usbased private charitable foundation estab lished genentech provides financial support spirit roche supports projects run qualified nonprofit us charitable organisations community united nations childrens fund unicef malawi fund support health science education patient education ing helped build classrooms pay school materials advocacy like desks books literacy resources addition joined unicef supporting primary school teacher training building new teacher training college southern malawi additionally roche provides financial sup community involvement roche business report illuminated dna move roche sole corporate sponsor competition aims promote science study science careers dna deoxyribonucleic acid essential part every broadening understanding life science research organism normally found chandelier idea creating chandelier modelled crystallised dna roche diagnostics germany helping teachers make intrigued dutch designer lucas maassen dna classroom experiments attractive vivid fragments crystallised roches molecular biology labora blue genes kit containing two dna experiments precise tory magnified glass version crystal normally descriptions lesson planning provided nominal fee visible microscope produced experimental kit complements theoretical instruction crystal manufacturer giving teachers students handson opportunity learn basic techniques molecular biology one thousand glass orbs later valerie crystal sister representing sister maassen never assem roche ireland supported primary school faced bled parents june vitra design terminating computer programme museum weil rhein germany art basel funds upgrade outdated computer lab show work true collaboration lucas maassen roche scientists part confrontations con schools computer room officially reopened may temporary dutch design exhibition museum donated computers roche ireland enabling school provide students new skills including literacy numeracy word processing arts culture roche actively cultivates supports groundbreaking con temporary art cultural projects favour creative activi ties explore parallels innovation arts science roche commissions offers contemporary music artists challenge opportunity forge new frontiers field started every second year recognised contempo science education rary composer selected recommendation artistic director lucerne festival partner roche business founded excellence innovation sci commissions commissioned work premiered ence help develop future scientists public lucerne festival summer composer standing life sciences supporting programmes conductor matthias pintscher granted sixth roche enhance science education draw talent science careers commissions award composition chute dtoiles engage outstanding young scientists teachers also support creative expression monthly roche switzerland roche active supporter swiss youth n jazz events together rochefounded museum science foundation raises awareness appreciation tinguely birds eye jazz club bring inventive science among children young people support jazz community basel roche continents foundations national competition study weeks students science music fine arts across swiss talent forum think tank young adults among europe selected spend week salzburg austria activities salzburg festival attend workshops explore common ground creativity art science simply science website designed generate interest among young people life science hosted swiss foun dation name website piloting innovative national secondary school class competition science roche business report community involvementgene sequencing zoo kumari asian elephant calf smithsonian national zoo lived months dying persistent internal bleeding searching cause bleeding pathologists zoo discovered aggressive herpes virus specific elephants elephant endotheliotropic herpes virus eehv since zoo launched study eehv animal diseases using powerful gene sequencing device donated roche gs junior system installed smithsonian conservation biology institute system support research causes high mortality rates among elephants living captivity growing number eehv cases wild scientists believe disease may connected loss animals natural habitat community environment latvia one highest infant mortality rates one lowest birth rates europe roche latvia collabora organisation individuals committed tion neonatology obstetrics experts initiated save using resources support local communities protect newborns aiming reduce infant mortality rates half natural resources us genentech gives back week based situational data assessments series recom opportunity employees roche affiliate mendations made ranging improving medical infor support communities employees helped mation quality improving usage ultrasound exami donations form cash goods employee time nations ministry health adapted new policies nonprofit organisations participated volunteer implemented proposed recommendations projects donated air miles barrels educational supplies clothing food information found wwwrochecom examples community involvement indicators measures success humanitarian science arts culture community social projects education environment roche logistics consultations scientists workshop roche experts workshop workforce volunteers employee volunteers disabled trainers leaders local programmes engagement employee walkers raising sciencetechnology hours collaboration team building events funds vulnerable educational materials service agencies children volunteer tutors secondee days mentors community individuals screened teachers professional museum visitors individualsfamilies beneficiaries student teachers trained development workshops arts science students assisted community children enrolled children aided tutoring joint projects services secondary school secondary students children creativity family counselling disabled children assisted conducting research workshops sessions concert audiences homes renovated infrastructure social service centres placement students creativity workshops cultural groups sustained system renovated teaching methods established recreation programmes changes prototype schools adopted performance established constructed visitshits online commissioned music public sites cleaned mobile health clinic oper resources ongoing museum ations construction training course graduates operations community involvement roche business report value innovation mining biotech roche penzberg innovation creating value local economy roche penzberg biotech hub located site former coal mine outskirts bavarian town penzberg germany roche bought site since invested billion euros stateoftheart facility creating additional jobs employees holds university degree impact local economy innovationdriven company like roche penzberg enormous creating far aboveaverage wealth community people employed roche penzberg extremely well qualified high salary levels bringing increased tax receipts consumer spending order make products roche needs highqualified labour also supplies goods services result innovation triggers substantial multiplier effect local economy germany whole increase employment since employees companies co sn ump ti companies coth pr nies salary nv e st ei n cs lu p pl nt billion euros invested since biggest payer business tax penzberg region u p distinct external network academics ply biotech companies complete biotech value chain tax science patients social security companies horst seehofer prime minister bavaria penzberg prime example bavarias state successful modernisation drive roches strong society commitment made difference one also benefited country small mining town rural upper bavaria internationally networked location research innovation generating sizeable number highly qualified jobs web httpwwwrochecomvalueofinnovation roche business report value innovation penzbergenindd impact penzberg germany production value every euro spent roche penzberg generates additional euros germany employment every job roche penzberg generates additional jobs germany state society roche tax penzberg social security state society nv e st ei n cs lu p pl salary companies nt co sn ump ti sec ur ito yct iaa lx n roche direct impact employees pply u salary indirect impact companies employees indirect impact companies penzbergenindd percent reduction greenhouse gas emissions roche business report safety security health environment increased energy efficiency per employee reduced ecological impact per employee decreased water consumption roche business report safety security health environment key figures roche accident rate rar track reach goal energy efficiency gjemployee track reach goal co efficiency temployee track reach goal total environmental impact million impact pointsemployee track reach goal roche refer safety security health environmen inclusion reporting based analysis iden tal protection approach sense tified following priority topics responsibility methodically issues occupational accidents occupational illnesses concerning quality productivity costefficiency energy consumption use sustainable energy total ecobalance ecological impact operations strive continuous improvement wherever pos total toxicity waste water sible economically viable seek sustainable longterm closing gaps identified internal audits improvement throughout organisation changing behav compliance laws regulations iour adapting equipment recent standards improvement performance suppliers developing innovative processes service providers reduction total risk load education employees relevance materiality maximise value reporting strive provide improving monitoring information balanced relevant stakeholders performance identified following topics believe material business thus sufficiently important reported employee engagement training people respect health integrity wellbeing prevention key effective management environment conservation resources around employees safety health environmental material assets functional efficiency protection teams roche site identify risks business continuity cost develop mitigation plans communicate policy guide compliance external internal regulations lines employees stakeholders regards looked believe education awareness training best material issues considered potential future develop ways foster employee engagement responsibility ments analysed need feasibility act defined perfor mind conduct regular training sessions mance indicators set goals targets regional conferences workshops provide online tools local languages employees employees materiality influenced external internal factors participated hours training instance external regulations laws may affect strategy reporting conventions within industry stakeholder regularly review effectiveness management expectations internally organisations policies strategies system encourage employees identify areas improve goals determine materiality issue con ment using database best practices employees sidered factors identifying areas frequently share knowledge exchange new ideas pro roche business report safety security health environmentcedures proposals database ecompetition adopted areas within organisation started roche ecompetition gives employees annual roche responsible care award recognises opportunity contribute ideas suggestions best contributors applications good practices improving sustainability culture performance also employees received entries award raises awareness environmental protection encour announce winners first quarter ages sustainability identifying cost savings environ mental protection activities audits assessments assess performance comparing results ecompetition submissions resulted significant laws regulations internal standards set improvement variety areas including energy conserva organisations international chamber com tion waste reduction decreased consumption water merces business charter sustainable development inter raw materials reduced air pollution additionally num national organisation standardisation chemical ber submissions addressed social aspect sus industrys responsible care programme tainability suggestions improving certain manufacturing processes resulted major cost savings conduct internal audits every three years chemical ideas including measures reduce energy consumption pharmaceutical diagnostics manufacturing sites airconditioning systems proved useful multiple sites critical operations stipulating necessary improve ments audit audit frequency facilities sixth edition ecompetition winners determined risk potential strategic importance past per selected entries reducing energy consump formance sitespecific circumstances plant man tion got interest well improving logistics agement local officers conduct frequent spot respect packaging transportation concepts checks inspections assess compliance stan interesting idea references use heatdriven dards sterling engine cooling purposes expect contract manufacturers suppliers service pro viders meet standards ensure compliance standards thirdparty auditors seeing light turning retained us periodically inspect operations sup pliers issue recommendations improvement genentech south san francisco goal reducing event unsatisfactory performance may terminate energy use building campus within five contract refuse award new contract supplier years help achieve members green genes nearly member employee club supports green practices audits elected find ways eliminate reduce unnecessary lighting internal audits sparked idea member green genes followup energy team club formed army darkness first time volunteers audited buildings worked document external audits ing lighting controls conditions operating hours followup even though many campus buildings equipped first time occupancy sensors automatically turn lights audit found ineffective lighting controls areas light direct materials suppliers switches lights always many issues resolved quickly easily others sched internal followup audits sites improved uled lighting system upgrades army darkness performance recommended improvements follow efforts contributed lighting projects saving esti ing audits included increasing involvement line mated three million kilowatt hours per year management improving risk analysis safety security health environment roche business report details found chapter manufacturing increased sales expenditure environmental protec procurement tion limited environmental harm reduced higher eer value thus ecoefficiency minimising environmental seek improve eer reducing material energy footprint consumption waste using renewable resources efforts resulted eer improving part commitment sustainable development proactively seek employ new sustainable technolo gies processes minimise impact environ ecoefficiency rate eer ment established groupwide goal ecobalance sales ever management roche site may establish strategies million chf objectives reducing environmental impacts environmental best suited local circumstances expenditure million chf total environmental impact per employee environmental million impact points improvement impact targeted improve ecobalance levels environmental impact points eer x ecoefficiency ecoefficiency aims minimising ecological damage maximising efficiency firms production processes addition expending million swiss francs envi achieved using less energy materials water ronmental purposes expenses safety security decreasing elimination hazardous emissions byprod amounted million swiss francs hence total ucts increasing recycling quantify ecoefficiency expenses measures approximately ecoefficiency rate eer ratio sales expenditures million swiss francs compared million swiss environmental protection environmental impact points francs decrease approximately accordance swiss federal office envi ronment foen efficiently business activity increasing energy efficiency goal reduce total energy consumption fossil fuels electricity gigajoules gj per employee levels levels ecobalance impact points longterm goal reduce energy consumption per employee approximately baseline levels roche ecobalance refers consumption energy resources pollution caused business also plan increase proportion sustainable energy activities thus describes total environmental impacts use total energy consumed strategy operations achieving objective first improve energy efficiency aggressively substituting fossil fuels sustainable allocating environmental impact points weighting fac energy tors ecologically relevant parameters consumption resources raw materials water energy energy conservation priority throughout group first waste emissions air water soil obtain main source greenhouse gas emissions view demand place earths ecosystems co second reducing energy con points added related total number sumption lowers operating costs systematic approach employees enables us monitor environmen energy management includes tal impact per employee million impact points constructing energyefficient buildings retrofitting heating cooling air conditioning installations roche business report safety security health environmentecobalance numbers impact points see box raw material primary energy emissions air water emissions water landfilled waste environmental impact per employee million impact points roche products adjusting range acceptable temperatures offices countries fuel reductions resulted savings approx workplaces million swiss francs purchasing energyefficient equipment including hybrid increase use sustainable energy bringing total dieselefficient cars sustainable energy consumption changing work processes reviewing employees travel needs improvements resulted overall decline energy consumption together slight increase continued focus responsible use number employees energy consumption gj per resources continuous reductions energy consumption employee surpassed target gj activities resulted improved energy usage several areas project team roche indianapolis improved organisational reduction energy use buildings stationary efficiency reduced international air travel leaders equipment gas fuel oil waste electricity three business units three facetoface meetings decrease car fuel consumption central celled person days productivity gained including eastern european middle eastern african indian avoiding travel days international domestic safety security health environment roche business report ecobalanceenindd flights avoided resulting saving approximately giga energy use type joules energy approximately tonnes co emissions swiss francs however overall area natural gas business travel reduction efforts less successful energy consumption air travel increased grid electricity lowering greenhouse gas emissions district heating greenhouse gas ghg emissions roche originate generation use energy goal improving energy air travel efficiency reducing energy consumption therefore also applies ghg emissions reduction measured waste tonnes per employee levels reduction levels expect achieve oil reductions substituting fossil fuels energy sustainable sources car fleet actively seek decrease ghg emissions establishing internal energy standards ensure new plants buildings greenhouse gas emissions co equivalent designed maximum energy efficiency optimising retrofitting existing assets total emissions reducing amount fuel use heat cool million tonnes operate sites thus able reduce ghg emis total emissions sions result energy saving measures per million chf sales tonnes energy use terajoules baseline total energy use total energy use per million chf introducing new technologies sales total energy use fuel cell technology chosen best option per employee refurbishing energy supply roche molecular diagnostics pleasanton california project engi neering team received innovation award reducing halogenated hydrocarbon emissions senior management roche molecular diagnostics halogenated hydrocarbons used refrigerants cooling equipment chlorinated compounds deplete fuel cells produce electricity heat hydrogen ozone layer whereas fluorinated partially fluorinated electrochemical reaction combustion similar considerable global warming potential battery get optimum overall efficiency heat exchangers persistent thus stay atmosphere long recover heat used heat buildings period time example chlorodifluoromethane commonly pleasanton site process producing usable used propellant refrigerant remains atmo electricity heat commonly known cogeneration sphere approximately years cogen combined heat power chp depending amount heat used site typical efficiency plan reduce halogenated refrigerants rate fuel cells ranges whereas roche sites sites acquired recent years electricitytoheat ratio approximately three two genentech ventana working towards sepa rate timelines roche business report safety security health environmentsince made significant progress reducing emissions air tonnes emissions halogenated hydrocarbons eliminating halons reducing fully halogenated compounds excluding genentech sites ventana vocs particulates recent acquisitions lack alternatives coun nitrogen oxides tries make complete elimination chemicals sulphur dioxide unrealistic nevertheless continue examine alternatives work refrigeration suppliers make reduc tions managing waste waste parameter ecobalance waste reduction halogenated hydrocarbons tonnes targets therefore reflected goal improve groups ecobalance maintain waste reduction goals individual sites however set inventory groupwide goal primarily large yeartoyear fluc emissions tuations waste construction demolition activities roche pharmaceutical diagnostics companies minimising air emissions produces relatively low volumes chemicals thus gener minimise emissions air variety technologies ates small quantities chemical waste nevertheless con practices priorities avoid pollutants reduce tinue reduce already low volumes waste pro duction quantities pollutants control remaining pollutant emis biotech products increases chemicalbased products sions line ecobalance goals overall objective declines genentech hillsboro site oregon usa keep emissions low levels achieved example diverted solid waste recent years landfills earning recycle work award local government emissions strategy prescribes continuous improvement programme manufacturing sites includes flue gas production pharmaceutical diagnostic products rose scrubbers reduce nitrogen oxides sulphur diox overall chemical waste x ide various incineration freezing processes general waste increased reduce release volatile organic compounds vocs may also reduce energy use accept responsibility waste generated opera tions including previously deposited sites land basel site commission installation fills permit landfilling last resort even freeze vocs waste air discharged manufacturing inert materials slag incineration ash buildings equipment process uses liquid nitrogen depending availability suitable local wastetreatment replace energy intensive process incinerating waste plants may dispose nonhazardous general waste air similar installation completed chemical authorised landfills manufacturing plant florence usa end switzerland roche companies continued clean emissions air low levels fluctuate hazardous waste landfills klliken bonfol year year result significant variability mer user kesslergrube landfill grenzach germany instance group emissions increased roche studying possible remediation options also x tonnes prolonged use emergency generator evaluating various remedial options former site belle single site ville new jersey usa june roche announced planned shutdown operations approximately acre site nutley new jersey consequence view future sale property roche accelerated existing efforts state regulatory oversight fully investigate remediate safety security health environment roche business report soil groundwater conditions site early remedia record organic emissions water total organic car tion activities either completed underway include bon toc processing wastewater treatment plant groundwater treatment soil excavation operation soil discharge wastewaters pollutants comply vapour extraction systems fully relevant regulations including pretreatment require ments elimination rates wastewater potential responsible party roche involved several treatment plants already high seek minimise investigations remediation projects different environ contamination water mental sites throughout us reducing discharges toxic poorly biodegradable sub stances heavy metals waste tonnes reducing generation wastewater treating pretreating wastewater ozone cases non poorly degradable contaminants general waste produced result continuous efforts reuse reject water general waste reverse osmosis cooling towers boilers improved per million chf cooling processes water consumption decreased sales million cubic metres penzberg site ger chemical waste many instance selfpowered highefficiency wastewater produced treatment plant earned several awards innovation envi chemical waste ronmental responsibility local programmes iden per million chf tified opportunities reduce water consumption sales genentech south san francisco site evaluation identified improvements reverse osmosis portion water puri fication plant could save estimated million gallons conserving protecting water resources approximately swiss francs per year furthermore roche supports global efforts promote water protection pilot study launched treat reuse wastewater conserve water reserves improve access clean drinking neutralisation cascade successful could save water longterm goal reduce total wastewater toxicity additional million gallons well approximately baseline meantime con swiss francs per year tinue investigate reliable performance indicators mea surement methods establishing baseline strive water usage discharge stabilise water consumption throughout group half water draw used cooling circuits water withdrawn water chemically contaminated discharge million cubic metres analysis rest purified treatment plants water used released waterways million cubic metres wastewater discharged even though operate sites consume large treatment plant volumes water areas water scarcity still adopt million cubic metres conservation reduction programmes according local organic matter conditions needs example californian sites use discharged drought resistant landscaping sites reduce water watercourses consumption treatment tonnes collecting recycling water cooling towers creating heavy metals closedloop system discharged reusing cleaning water next first rinse recycling watercourses used water treatment kilogrammes reducing cooling requirements improving cooling pro cesses improving heat recovery roche business report safety security health environmentin transferred million cubic metres water water management local issue therefore roche treatment plants resulting discharge tonnes purposely decided set global target surrounding water organic matter addition discharged kilogrammes management encourage local targets locally heavy metals leaching metal pipes water management closely therefore effectively operations watercourses monitored heavy metal emissions roche sites low levels thus new processes activities may significant supporting biodiversity effects amounts emitted example cleaning galva nised equipment dismantled mannheim roche supports principles resource stewardship defined site germany resulted increase zinc washouts convention biological diversity cbd three main objectives covering conservation biological diver toc emissions could reduced substantially roche sity sustainable use components fair equitable rio de janeiro plant modifying processes using new clean sharing benefits use genetic resources ing agents well different production programme avoid use noncommodity natural resource materials water management source products discovery development water considered basis life equally important pharmaceuticals however discover develop com industrial activities thus production pharmaceuti mercial product derived natural plant microbial animal cals diagnostics possible sufficient amounts genetic materials use resources guided clean water availability highquality water critical principles goals cbd business almost processes chemical biotech pharmaceutical diagnostics manufacturing involve water otherwise operate facilities areas pro reagent solvent cleaning agent globally poor quality tected high biodiversity values roche sites require water resulting higher costs purification risk access city infrastructure located urban product contamination pharmaceutical industry addi environments tion water used energy carrier refrigeration heating installations safeguarding employees appropriate water management thus must roche property operations roche group sites working pro grammes reduce water consumption recycle reuse health safety water context completed assessment employee health safety first priority primary exposure roche businesses water risks last objectives keep roche accident rate rar two years focus availability water suffi reducing reduce cient amounts acceptable quality roche illness rate rir less rar cor responds number working days lost due occupa first evaluation using water tool world business tional accidents per employee year roche site rir council sustainable development identified six sites corresponds number working days lost due occu could eventually face water scarcity near future tool pational illnesses per employee year uses statistical information bodies food agriculture organization un world resources insti maintain integrated programme employee consulta tute university new tion workplace inspections training across business areas approach promote strong safety culture second evaluation concentrated future development empowers employees report address safety site surrounding area water competitors issues expect similarly rigorous policies con could negatively influence future growth finally two sites tractors also encourage safety wellbeing identified need indepth water analysis employees selling discounted protective equipment respect development improvements water recreational activities conducting bicycle safety checks supply among activities roche legans madrid spain optician worked site adjusting lenses selling safety security health environment roche business report glasses four days roche pleasanton usa volunteer tion regarded significant business risk roche small ergonomics team known locally ergo angels performs specialist team comprised members global competi dropin ergonomic evaluations employees tive intelligence security legal data compliance group security briefed employees roche diagnostics rotkreuz ongoing efforts improve workplace roche basel topics campaign contin safety resulted decline approximately ued remaining r sites extended number workrelated accidents per million working hours operational areas needed employees reported occupational accidents increase frequency compared security activities included conducting resulting number lost days increased western europe security workshop mannheim germany overall roche accident rate site security officers together chief security went officer discussed priority issues product counter feiting information security although number reported cases occupational ill nesses increased cases number working days lost declined pharmaceuticals environment result roche illness rate decreased consider entire lifecycle drugs taking steps minimise release pharmaceuticals environment occupational accident illness profile remains consis stages tent slips falls repetitive strains representing majority workrelated incidents however traces pharmaceutical products enter environment report one workrelated fatality employee fell variety ways including manufacturing process cycling one building another campus tragi improper disposal unused medicines natural cally died days accident process following normal patient use patient use however generally recognised primary contributor employee safety health evidence suggests exposure trace concen basis trations surface ground drinking water pose roche accident rate harm human health risks aquatic life thought roche illness rate greater scientific studies identified short number term effects exposure lowlevel concentrations workrelated pharmaceuticals research conducted accidents evaluate potential longterm impacts therefore recognise cases need research possible effects support workrelated scientific work field illnesses workrelated design manufacturing sites reduce risk active fatalities ingredients entering wastewater also support pharmaceu workrelated tical takeback programmes employ proactive measures accidents prevent release products environment per million working offering financial incentives ensure unused hours dated products returned retailers others supply chain establishing policies require returned waste pharma security ceutical products incinerated rather disposed goal protect employees visitors physical landfills assets intellectual property products harm loss supporting research effects pharmaceuticals roche started information security awareness environment campaign addressing first priority employees working providing environmental risk assessments authorities r departments theft loss business critical informa new medicines roche business report safety security health environmentlegislation compliance environmental protection meet local laws regulations although policies basis target date often rigorous external standards improve energy efficiency gjemployee fully track registration chemical materials according european legislation registra increase share sustainable tion evaluation authorisation restriction chemicals energies total energy consumption reach requirements globally harmonised system classification labelling chemicals reduce co emission per employee line improving energy nine consecutive years prior incurred sig efficiency nificant fines sherelated violations however reduce total environmental impacts assessed small fines two minor infractions calculated ecobalance according respect worker accident resulting four lost days swiss federal office breach management regulation relating environment bafu per employee specific risk assessment particular process reduce total waste water toxicity goals education web basis target date environmental protection wwwrochecomenvironment improve education increasing eer ecobalance wwwrochecom training per employee factsheetecoefficiencypdf goals wwwrochecomshegoals average four hours per year performance wwwrochecomsheperformance services wwwrochecomsheservices policies guidelines position papers wwwrochecomresponsibility environmentshemanagementpolicyguidelinesandauditshtm safety basis target date improve roche accident rate rar rar reduce number occupational accidents causing lost working days cases per working hours keep roche illness rate bring number cases occupational illnesses causing lost working days cases per working hours safety security health environment roche business report value innovation n eric e g revenue research develop cycle drug ment development e ar ti r k e e patent protection years rocephin whos model list essential medicines cludes active ingredients developed roche one rocephin cefriaxone highly effective treatment many bacterial infections including purulent meningitis approval rocephin quickly became roches topselling drug worlds number one injectable antibiotic generic pro duction ceftriaxone naturally attractive proposition patents expired time ceftriaxone generics market produced different countries web httpwwwrochecomvalueofinnovation roche business report value innovation patentprotectionenindd innovation pharmaceutical industry lasting contribution world health discovery development new drugs high risk development cost billion swiss francs take eight twelve years complete one five drug candidates average receive regulatory approval even patented drug copied easily quickly composition must declared innovation continue drive medical breakthrough investment research deve lopment compensated new drugs must adequately protected patents come patents temporarily confer exclusive right market products protect ensuring innovation rewarded search new treatments continues offpatent products replaced generics made avail g e n eric ida er yng ete ait f r sa cn ad ti ole nad able society low cost perpetuity l e es ato opti id ar n p r te cycle drug research develop ment e rse tin g c lin ic l development e ar investment clinic l yu ed ai ss prof patrick aebischer prsident cole poly technique fdrale de lausanne patents essential research life sciences protect knowledge raw material provide incentives highrisk investments patentprotectionenindd foundation years ago roche years specialised leader researchfocused healthcare combined strengths pharmaceuticals diagnostics roche business report corporate governance roche committed serving stakeholders basis successful implementation commitment stakeholders corporate governance principles accordingly put focus business activities sustainable value creation innovation prescribe management culture conforming recognised standards corporate governance policy transparent communication remuneration report roches success depends abilities dedication people recognition forms basis performanceoriented remuneration policy system roche business report corporate governance corporate governance roche committed serving stakeholders basis curricula vitae members board directors successful implementation commitment cor corporate executive committee published porate governance principles accordingly put focus website business activities sustainable value creation innova tion prescribe management culture conforming rec details please refer following report ognised standards corporate governance policy transparent communication board directors strong board directors represents interests shareholders stakeholders highly skilled th annual general meeting agm roche holding managers act integrity extremely important ltd march shareholders reelected john bell andr hoffmann franz b humer members board dow jones sustainability indexes designated directors term two years provided arti roche supersector leader healthcare fourth con cles incorporation secutive year sustainability core business practices award reflects commitment running organising meeting immediately following agm business way ethical responsible creates board directors determined structure compo longterm value stakeholders sition committees shown corporate governance report sets structures agm march board directors nom processes rules roche takes basis well inate andreas oeri pius baschera paul bulcke william functioning corporate governance roche com burns christoph franz deanne julius arthur levinson plies relevant corporate governance requirements peter r voser beatrice weder di mauro reelection particular applicable laws swiss stock exchange board term two years provided articles six swiss exchange directives including commentaries incorporation thereto swiss code best practice corporate governance promulgated swiss business federation bruno gehrig vicechairman board directors economiesuisse companys internal governance frame lodewijk jr de vink longterm members board work particularly articles incorporation bylaws directors decided retire members board embodies principles needed ensure com directors board directors thanks members panys businesses managed supervised manner long valuable contribution successful continu consistent good corporate governance including ing development roche necessary checks balances agm march board directors addi printed annual report contains selected links tionally nominate severin schwan election board roche website wwwrochecom readers thus provided term two years provided articles incorpo snapshot company reporting date ration also directed sources consult time uptodate information corporate governance roche whereas annual report covers single finan cial year ending december website contains informa tion permanent nature well latest roche news companys articles incorporation bylaws httpwwwrochecomaboutrochecorporategovernancehtm roche business report corporate governancecorporate executive committee information relating corporate governance sophie kornowskibonnet former general manager roche pharma france appointed head roche part group structure shareholders nering groups headquarters basel joined roches operating businesses organised two divi enlarged corporate executive committee new member sions pharmaceuticals diagnostics pharmaceuti february reporting severin schwan ceo cals division comprises two business segments roche roche group succeeded dan zabrowski took pharmaceuticals chugai whereas genentech head roche applied science diagnostics division former third segment integrated roche phar located penzberg germany february dan maceuticals diagnostics division consists fol zabrowski member diagnostics leadership team lowing five business areas applied science diabetes care reporting roland diggelmann coo division molecular diagnostics professional diagnostics tis roche diagnostics since september sue diagnostics business activities carried group subsidiaries associated companies detailed jeanjacques garaud head roche pharma research information roche holding ltd significant sub early development pred member enlarged cor sidiaries associated companies including company porate executive committee retired roche june name listing information domicile share capital equity effective july mike burgess discovery interest listed finance report note translational area dta head oncology head roche group consolidated financial statements subsidi large molecule research assumed adinterim position aries associates head roche pharma research early development major shareholders listed finance report notes pred sits enlarged corporate executive com roche group consolidated financial state mittee john c reed appointed head roche ments equity attributable roche shareholders pharma research early development pred mem related parties pages note ber enlarged corporate executive committee succeed financial statements roche holding ltd significant ing mike burgess reporting severin schwan effective shareholders april andr hoffmann vicechairman board directors andreas oeri member board directors effective september daniel oday appointed coo chairman boards corporate governance sus division roche pharmaceuticals succeeding pascal soriot tainability committee serve respective capacities following resignation time roland diggel board committees representatives mann head asiapacific region roche diagnos shareholders group pooled voting rights receive tics succeeded daniel oday coo division roche diag remuneration set forth remuneration report nostics finance report note roche group consolidated financial statements related par information member board directors includ ties note financial statements ing years elected years roche holding ltd board executive remuneration terms end member corporate relationships exist sharehold executive committee listed pages ers pooled voting rights board directors corporate executive committee crossshareholdings capital structure information roches capital structure provided finance report notes financial statements roche holding ltd additional details contained articles incorporation roche holding ltd httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm corporate governance roche business report changes equity detailed finance report notes annual general meeting elects members financial statements roche holding ltd board directors staggered elections nominee voted separately see articles company share capital swiss incorporation roche holding ltd minutes francs divided fully paid bearer shares th annual general meeting roche holding ltd held nominal value swiss franc march restrictions exercise voting rights exception franz b humer william burns shares upon deposit shares voted without arthur levinson none members board restrictions directors member roches corporate execu authorised conditional capital tive committee served executive capacity addition nonvoting equity securities nes group subsidiary three financial years preceding issued bearer form form part current reporting period share capital confer voting rights nes con internal organisation board directors fers rights one share participate available division authority responsibilities board earnings liquidation proceeds following repay management remits board committees ment share capital roches nes rights per information control mechanisms available taining thereto including provisions protecting board dealings corporate management gov interests nes holders described articles erned bylaws incorporation roche holding ltd board directors roche holding ltd organised information debt instruments issued ensure group conducts businesses respon outstanding bonds provided finance report sibly focus longterm value creation note roche group consolidated financial state end roche board delegated certain responsibilities ments debt several committees composition chairpersons additional information employee stock options pro january described com vided finance report note roche group mittees authorities responsibilities defined detail consolidated financial statements employee stock options bylaws board directors equity compensation plans including detailed committees except presidium chaired information roche option plan roche independent directors restricted stock unit plan ff according bylaws board directors board roche issued options apart employee stock meeting may convened without chairman present options stocksettled stock appreciation rights ssars request members roche board meets options issued connection debt instruments year assess chairmans performance neither options awarded employees debt meeting attended chairman chaired instruments issued effect one vicechairmen roches share capital part management information system board directors informed important issues board directors corporate executive committee sales performance etc monthly basis board information member board directors access electronic information platform provides including years elected timely information board directors boards years terms end member committees system controls set forth corporate executive committee listed pages curricula vitae current former members last years bodies information including information board memberships available con tinuously updated internet httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance annualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochemanagement committeeshtm boardofdirectorshtm httpwwwrochecomaboutroche httpwwwrochecomaboutrochecorporategovernance managementexecutivecommitteehtm articleofincorporationhtm roche business report corporate governance board directors established system controls conducting operational audits group audit deter continuously monitored audit committee mines managements response risks surrounding corporate governance sustainability com business processes systems evaluates mittee consists following elements appropriateness completeness efficiency pro report operating financial risks risk management cesses controls action plans implement neces system sary changes enhancements developed together r oche system place identify manage businessauditee tracked completion type risks potentially affecting business roches statutory auditors see risk management charter sets approach chief compliance officer compliance officers accompanying responsibilities pharmaceuticals subsidiaries see diagnostics divisions global functions conduct safety health environmental protection depart mal risk assessment process least year ment must develop risk plans material risks corporate sustainability committee monitored deviations reviewed regular science ethics advisory group seag issues performance dialogues consolidated group risk relating genetics genetic engineering established report including target risk profile discussed corporate executive committee approved together members corporate executive committee group business plan also presented invited attend meetings board directors audit committee process subject regular report person agenda items concerning reviews findings presented audit committee situation warrants members enlarged cor full board porate executive committee may also invited attend f details risk management including risk factors board committees invite chairman board risk management charter see risk management corporate executive committee members deliver reports compliance website financial risk management committee meetings may elect commission inde specifically described finance report pendent expert reports call services consul system internal controls financial reporting see tants pages finance report internal audit g roup audit reports general counsel direct access gives regular briefings audit commit tee ongoing activities audit reports chief audit risk advisory executive attends audit com mittee meetings external auditors g roup audit independent appraisal function evaluates reviews groups activities service management annual audit plan yearly defined focus areas eg emerging markets thirdparty manage ment validated senior management presented audit committee roche group committed maintaining high standard internal control worldwide operations management responsible assessing business risks aspects oper ation implementing effective efficient pro cesses controls whilst ensuring compliance internal external rules regulations httpwwwrochecomcorporateresponsibilitybusinessethics riskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm additional information provided finance report note httpwwwrochecomcorporateresponsibilityhtm roche group consolidated financial statements risk management httpwwwrochecomcorporateresponsibility csrresearchanddevelopmentgeneticsandbioethicshtm corporate governance roche business report board board committees attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meetings f b humer b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink ch franz julius levinson oeri p r voser b weder di mauro member committee franz b humer invited guest board committee meetings year several blackout periods imposed corporate governance sustainability committee two senior employees prohibited trading com meetings approx hours pany stock following blackout periods effect composition boards committees remained december january unchanged since march april april board directors regularly conducts assessment june july performance october october members corporate executive committee blackout periods changed chairman maximum ordinary notice period twelve months board directors circumstances warrant management contracts fall within board directors met six meetings generally scope subsection annex six directive hours length addition full information relating corporate governance day meeting threeday visit major sub sidiary board committees met follows remuneration shareholdings loans presidium board directorsnomination commit details regarding remuneration shareholdings loans tee four meetings approx hours set forth separate remuneration report pages remuneration committee three meetings approx finance report notes hours roche group consolidated financial statements equity audit committee four meetings approx hours attributable roche shareholders related parties pages listed notes financial statements roche holding ltd board executive remuneration board executive share holdings pages figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activities remuneration committee members permitted contribute attend remuneration committee meetings matters concerning deliberated decided roche business report corporate governance participatory rights shareholders reports statutory auditors consolidated finan participatory rights shareholders defined cial statements financial statements roches articles incorporation roche shares found pages respectively years issued bearer restrictions admission finance report annual general meetings exception shares must deposited within specified period date kpmg received following remuneration services meeting admittance card must issued statutory auditors roche holding ltd audi shareholders name provided articles tors roche companies including chugai incorporation shareholder elect represented third party annual general meeting articles incorporation contain restrictions exercise voting millions chf rights quorum requirements stipu auditing services lated conformity swiss code obligations auditrelated services articles incorporation shareholders accounting services representing shares nominal value least million assurance services swiss francs request placement items tax consultancy services agenda annual general meeting must done total later days date meeting statutory auditors elected year annual change control defensive measures general meeting articles incorporation contain provisions mandatory bid rule swiss law applies information policy changeofcontrol clauses components provided articles incorporation corpo remuneration based roche nes would terminated rate notices published swiss official gazette event acquisition vesting period restrictions commerce daily newspapers designated preexisting awards would removed board directors basler zeitung finanz und wirtschaft options could exercised immediately lagefi le temps neue zrcher zeitung roche reports halfyear fullyear results business relationship statutory auditors reports published print online formats media annual general meeting roche holding ltd events addition detailed first thirdquarter sales fig march shareholders voted appoint kpmg ag ures published year april october kpmg statutory auditors based existing legal current list publication dates available english requirements swiss code obligations article german internet concerning maximum term office seven years relevant information documents including media auditor charge ian starkey replaced predecessor john releases investor updates presentations analyst morris auditorincharge starting business year investor conferences available internet fur information long auditors auditorin ther publications ordered email fax telephone charge serving capacities provided baselwebmasterrochecom statutory auditors participate audit commit tel tee meetings prepare written oral reports fax results audits audit committee oversees contact address investor relations f hoffmann assesses auditors makes recommendations la roche ltd investor relations group finance basel board information authorities responsibilities switzerland audit committee see article bylaws tel statutory auditors participated three meetings audit fax committee httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecommediahtm articleofincorporationhtm httpwwwrochecominvestorshtm corporate governance roche business report additional information including details specific contact persons available internet chief compliance officer compliance officers network chief compliance officer compliance officers network committed ensuring roche group code conduct consistently complied roche group also serves contact person shareholders employees customers suppliers general public issues relating implementation compliance code employees par ties become aware violations roche group code conduct bring attention managers supervisors report chief com pliance officer urs jaisli direct phone number email ursjaislirochecom disclosures treated confidentially addition end employees may anonymously report irregularities complaints mother tongue via speakup hotline addition roche established business ethics inci dent reporting beir system enables chief compliance officer capture track monitor alleged violations initial reports local compliance offi cers resolution business ethics incidents recorded system local compliance officer receives specific concrete information material alleged violation roche group code conduct one certain predefined categories corporate governance sustainability committee audit committee board directors informed sub stantial violations chief compliance officer reports general coun sel also submits regular reports corporate gov ernance sustainability committee audit committee board directors nonapplicabilitynegative disclosure expressly noted information contained mentioned herein either nonapplicable omission construed negative declaration provided six swiss exchange corporate governance directive commentary thereto httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance codeofconducthtm httpwwwrochecomcorporateresponsibilitybusinessethics riskmanagementandcompliancehtm roche business report corporate governance corporate governance roche business report remuneration report remuneration report principles summary main activities roches success depends abilities dedication outlook people recognition forms basis perfor following key developments decisions manceoriented remuneration policy system remuneration committee assisted consultancy roche strive create innovative medicines diag towers watson regularly tracked base pay roche nostic products benefit patients requires outstand directors market data directors pay lead ing performance employees takes continuous ing global pharmaceuticals companies major innovation help patients sustain revenues create long swiss companies base remuneration roche direc term value innovation enables us pay competitive compen tors remained unchanged years sation employees distribute rising dividends base salaries fixed paid corporate executive com stockholders dividend increase th mittee cec members remained unchanged except year row one primary aims remuneration case daniel oday daniel odays base salary policy thus encourage longterm focus align man increased following promotion coo division roche agements interests interests roches shareholders pharmaceuticals holders roches nonvoting equity securities nes bonus variable paid cec members con sist entirely cash payments except case severin year remuneration committee roches board schwan reflecting sales growth strong growth directors meets least twice sets remuneration earnings per share nonvoting equity security board members members groups corporate development rich developed pipeline executive committee base pay bonuses stocksettled stock stocksettled stock appreciation rights ssars variable appreciation rights ssars policy decisions pension ssars granted cec members vest together benefits terms performance share plan psp awards three years exercised within seven determined annually board directors acting upon years grant date unexercised ssars lapse without recommendations remuneration committee compensation since fair value ssars calculated grant date using trinomial model remuneration committee tracks market data salaries american options details see leading global pharmaceuticals companies ssars granted strike prices reports findings full board external consulting nes price december time firm towers watson assists roche performing market com value recipients change roches parisons information remuneration committees remit nes price improves powers procedures making remuneration decisions performance share plan psp awards variable found bylaws roche board directors case psp psp psp also outlined sections principles cycles payout award targeted nes governing specific remuneration components psp cycle plans key performance met ric total shareholder return tsr calculated three month moving average constant chf exchange rates remuneration committee decided chief executive officer ceo cec members must acquire roche shares andor nes equivalent two annual base salaries ceo one annual base salary cec peer set abbott laboratories amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmith kline johnson johnson merck co novartis pfizer sanofiaventis takeda httpwwwrochecomaboutrochecorporategovernance abb credit suisse holcim nestl swiss ubs zurich insurance articleofincorporationhtm group actelion nobel biocare sonova straumann synthes roche business report remuneration reportmembers respectively end retain key principles underpinning policy holdings long serve cec focus value creation addition applicable statutory provisions roches long pay performance term incentive plans include option partially reclaim enabling employees share companys success distributed compensation result special circum fairness transparency remuneration decisions stances clawback details see balanced mix long shortterm remuneration com ponents starting restricted stock units rsus nonvoting market competitiveness equity securities vesting period three years introduced new remuneration component partially replac ing ssars options result better alignment roche longterm incentives value ssars awards reduced balance awarded form rsus company incur additional costs result change aim strengthen align ment managements interests interests roches shareholders groups longterm success previous years remuneration report submit ted separately advisory vote annual general meeting details please refer following sections remuneration report remuneration policy roche regularly reviews policy principles remuner ation part framework employee policies aimed motivating retaining current employees attracting tal ented new ones helping roche employees perform consistently high levels remuneration policy designed foster value creation reinforce culture performance innovation applies nonmanagerial employees managers ssars psp starting restricted stock units rsus remuneration components intended align managements interests shareholders hold ers nonvoting equity securities give participating managers additional incentive achieve continued value growth form longterm total shareholder returns creating value roche investors management benefits well added value created investors manage ment penalised receiving less see also finance report note roche group consoli dated financial statements related parties notes financial statements roche holding ltd board executive remuneration board executive shareholdings pages remuneration report roche business report remuneration components december remuneration committee determines base pay bonuses blocked nonvoting equity securities bonuses payable chairman board mem nes awards stocksettled stock appreciation rights bers corporate executive committee respect ssars performance share plan psp starting current reporting year based performance restricted stock units rsus support fundamental aforementioned objectives time remuner aims roches remuneration policy remuneration ation committee also decides form bonuses components linked companys financial perfor awarded cash payments andor blocked nonvoting equity mance commercial success thus align interests securities roche employees shareholders c stocksettled stock appreciation rights ssars explaining principles govern various remu stocksettled stock appreciation rights ssars plan neration components report details amounts paid introduced january establishing uniform system member board directors components remuneration throughout roche ssars entitle holders chairman boards remuneration amount benefit financially increase value roches remuneration component paid member corpo nonvoting equity securities grant date rate executive committee exercise date base pay ssar awards allocated individually remuneration base pay cash payment determined position committees discretion based salary market data leading global pharma ceuticals companies reflects individuals abilities experi restricted stock units rsus ence performance time pay increases likewise starting restricted stock units rsus nonvoting linked individual performance take account prevail equity securities vesting period three years ing market conditions companys overall financial introduced new remuneration component partially replac situation ing ssars options result better alignment roche longterm incentives value ssar awards remuneration committee makes reviews final reduced balance awarded decision base pay pay increases paid chair form rsus man board directors members corporate executive committee remuneration e performance share plan members board members corporate executive committee members senior management currently individu b bonuses als worldwide participate performance share plan bonuses awarded individual contributions value cre psp established periods three years ation go beyond normal job expectations meant based threeyear comparison total share incentive strive outstanding results create holder return tsr peer companies new business opportunities bonus amounts linked three overlapping performance cycles psp group divisional profits sales growth operating profit psp psp psp capital charge opac earnings per share nes closed december growth pipeline achievement measurable qualitative individual functional performance objectives terms performance share plan conclusively competitive reasons roche disclose individual determined board directors annual basis acting performance objectives members corporate executive upon recommendations remuneration committee committee roche business report remuneration reportf ratio corporate executive committee variable remuneration elements bonuses ssars psp relative fixed base pay end ssars criteria bonus starting ssarsrsus psp individual target value assessed max end ssars consideration performance starting ssars based annual base pay competitors rsus measured january macroeconomic development first year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development blocked nes determined determined performance nes performance nes grant grant performance criteria group objectives group individual contributions group performance divisional business upon remuneration tsr relation performance individual committees decision tsr performance objectives considering profit discretion peer set sales growth opac operating profit capital charge earnings per share nes growth pipeline split group objectives na b individual objectives na remuneration board directors bonuses salaries chairman board corporate executive committee directors members corporate executive committee year remuneration committee roches board set remuneration committee taking account directors sets remuneration board members mem revisions roches remuneration policy market comparisons bers roches corporate executive committee base pay leading pharmaceuticals companies manage bonuses ssars policy decisions pension benefits ment changes terms performance share plan determined annually board directors acting upon recommenda remuneration vicechairmen board tions remuneration committee remuneration board members consists fixed cash payments set committee tracks market data salaries leading discretion remuneration committee global pharmaceuticals companies reports findings remuneration committee assisted consultancy towers full board information committees remit powers watson tracked cash payments roche directors procedures making remuneration decisions market data directors pay leading global found bylaws roche board directors pharmaceuticals companies major swiss compa also outlined preceding sections report nies principles governing specific remuneration components following pages provide detailed information remu neration paid member board directors member corporate executive committee includes comparisons remuneration paid previous years httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm remuneration report roche business report remuneration members board directors members board directors awarded members board directors received fixed shares nonvoting equity securities stocksettled stock remuneration cash payments shown remuneration appreciation rights ssars members board directors table board activities basic remuneration board directors william burns received honoraria amounting total remained unchanged since remuneration mem us dollars swiss francs serving mem bers board directors remain unchanged ber board directors chugai pharmaceutical co ltd arthur levinson received payments consulting work serving board genentech amounting list members positions committee memberships chairmanships see us dollars swiss francs remuneration members board directors additional compensation additional special compensation remuneration committee memberschairs chf chf chf f b humer see b highest total remuner see b highest total remuner see b highest total remuner ation paid member ation paid member ation paid member board directors board directors board directors b gehrig hoffmann p baschera j bell p bulcke w burns see l j r de vink ch franz julius levinson see oeri p r voser b weder di mauro total exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board b highest total remuneration paid member chairman board since handover executive board directors function ceo annual general meeting march chairman franz b humer member board receive additional ssars nes highest total remuneration chairmans programmes psp rsu longer enrolled remuneration consists base salary bonus awards roche ssars programme roche business report remuneration reporthighest total remuneration paid member board directors chf chf chf salary bonus cash payment total pension fundsmgb roche connect total value detailed calculation remuneration see annual report mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes annual expense allowance chf payments tax consulting services chf chugai advisory mandate usd chf including employer contribution ahvivalv chf c stocksettled stock appreciation rights ssars horst teltschik former member board december franz b humer william burns directors received honoraria amounting euros members board directors holding swiss francs serving boards several ssars due former positions members roche subsidiaries germany corporate executive committee held stocksettled stock appreciation rights ssars shown ssars table additional remuneration paid franz b humers ssars currently value remuneration members corporate executive committee general provisions assigning authority total remuneration paid board directors decisions corporate executive committee remuneration members board directors received remuneration committee board directors remuneration totalling swiss francs outlined pages remuneration report swiss francs remuneration members corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee prorated remuneration period april december including chf loss pension rights granted former employer contractual agreement remuneration report roche business report b bonus except case severin schwan members cor remuneration committee board directors deter porate executive committee receive bonus mined corporate executive committee members bonuses cash payment due end april december based performance severin schwan receive bonus form roche agreed objectives nonvoting equity securities blocked ten years roche nonvoting equity securities granted end april bonus bonus bonus bonus total total total chf chf chf schwan cash payment blocked nonvoting equity securities total bonus ayyoubi cash payment blocked nonvoting equity securities total bonus r diggelmann cash payment blocked nonvoting equity securities total bonus hippe cash payment blocked nonvoting equity securities total bonus g keller cash payment blocked nonvoting equity securities total bonus oday cash payment blocked nonvoting equity securities total bonus total member corporate executive committee prorated remuneration period april december calculation value consideration reduction value due blocking period years c stocksettled stock appreciation rights ssars closing price roche nes grant date ssars ssars shown ssars table vest three years grant date vested ssars introduced roche january place stock exercised converted nes within seven years grant options ssars entitle holders benefit financially date unexercised ssars lapse without compensation increase value roches nonvoting equity securities nes grant date exercise date fair value ssars calculated grant date strike price ssars terms multiyear plan using trinomial model american options trinomial roche business report remuneration reportmodel effective method valuation american call numbers ssars strike prices expiry dates options considers possibility exercising option grant values ssars shown ssars table time prior maturity called american option com numbers ssars calculated time pared european option allows exercise issue entered values table maturity date ssars granted strike prices nes price december currently value recipients could change roches future nes price improves information trinomial model american options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar wwwrochecom trinomialmodelpdf see strike prices table ssars stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee performance share plan psp rities market prices dividend yields ie total share members corporate executive committee holder return tsr calculated chf constant members senior management currently individu exchange rates reduce effect shortterm market fluc als worldwide participate performance share plan psp tuations security prices averaged three months october december prior start performance psp moved overlapping threeyear performance cycle three months october december cycles new cycle beginning year end cycle thus three cycles progress psp psp psp previous years psp roche securities perform better average peer psp psp psp set roches tsr increases least cycle closed december without awards tar board directors elect increase nes award geted nes maximum award double original level reserved target number nes according psp plan requires provisions plan number nonvoting roche securities perform well better equity securities nes reserved partici peer set event investment roche pants cycle number securities actually awarded securities underperforms average return delivered depend whether extent investment peer companies fewer nes awarded roche securities shares nes outperforms average return investment securities issued peer set comparator companies comparisons based secu see footnote remuneration report roche business report performance share plan psp total estimated value psp awards awards nes nes nes targeted awarded awarded awarded target number target number number nes nes psp nes psp psp psp psp psp value chf value chf value chf value chf schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee total estimated value psp none originally targeted nes awarded psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved nes reserved plan members e indirect benefits corporate executive committee shown table employer contributions made social security board directors decide actual level nes schemes pension plans groupwide employee stock cash equivalent awards cycles purchase plan roche connect respect members close financial years corporate executive committee shown indirect respectively aim psp provide incentive benefits table participants achieve steady value growth roche connect voluntary stock purchase plan offering end psp cycle based three employees opportunity buy roche nonvoting equity month moving average distributed dividends totalling securities nes amount equal annual billion swiss francs billion swiss francs salary discount nes purchased plan billion swiss francs billion swiss subject holding period four years switzerland francs tsr roche securities nes shares ranked th compared peer set companies operat ing industry therefore according terms plan participants received none originally tar geted nes see table details roche business report remuneration reportindirect benefits payments pension fundsmgb ahvivalv roche connect tax consulting services insurances chf chf chf chf schwan ayyoubi r diggelmann hippe g keller oday total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits f remuneration emoluments loans ahvivalv swiss francs payments members corporate executive committee additionally already included corporate executive committee mem receive annual expense allowances swiss francs bers total remuneration swiss francs roland diggelmann received prorated amount unvested ssars targeted psp nes awards lapsed swiss francs totalling swiss francs without compensation silvia ayyoubi daniel oday received nonrecurring spe pensions totalling swiss francs paid cial payment swiss francs years former corporate executive committee members service company maximum regular period notice members cor due contractual obligations roche paid daniel porate executive committee months contractually oday alan hippe swiss francs swiss agreed severance payments exceeding payments francs respectively childrens schooling costs notice period previously included employment con tracts eliminated lapsed respectively expenses totalling swiss francs paid roland future therefore severance payments longer agreed diggelmann former position change control clauses employment contracts time provision made severin pascal soriot coo division roche pharmaceuticals schwan alan hippe receive supplementary death took new responsibilities outside company start disability benefits companyfunded retirement benefits ing september received following payments based event early retirement insurance benefits existing contractual obligations salary prorated fully funded single payment payment swiss francs bonus prorated cash pay included total remuneration swiss francs ment swiss francs payable april paid corporate executive committee previous year form roche nonvoting equity securities blocked three swiss francs years amounting swiss francs nes calculated based market value average last three months g highest total remuneration paid member granted beginning january corporate executive committee expense allowance prorated swiss francs payments severin schwan ceo member corporate tax consulting services swiss francs employer con executive committee highest total remuneration tribution pension funds etc swiss francs remuneration report roche business report highest total remuneration paid member corporate executive committee chf chf chf salary bonus cash payment blocked nonvoting equity securities total ssars grant value according trinomial model american call options pension fundsmgb insurances roche connect estimated value targeted awarded nes according performance share plan awardsvalue nes total total value calculation value consideration reduction value due blocking period years reduced market value detailed calculation remuneration see annual report trinomial model american call options value described remuneration members corporate executive committee c stocksettled stock appreciation rights ssars mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits basic rules detailed calculation see remuneration members corporate executive committee performance share plan footnote respectively includes annual expense allowance chf payments tax consulting services chf excluding employer contribution ahvivalv payments h total remuneration paid members table shows impact effective corporate executive committee remuneration current members corporate execu members corporate executive committee tive committee past seven years received remuneration totalling swiss francs swiss francs including ahvivalv due movement price nonvoting equity security strike prices ssars granted years indi additional remuneration mentioned cated table nonvoting equity payments paid current former members cor security price december therefore cur porate executive committee rently worthless table shows originally disclosed val ues currently outofthemoney ssars added compensation paid member ot cor alignment interests managers porate executive committee shareholdersholders nonvoting equity securities ssars psp remuneration components intended performance targets met psp programmes align managements interest shareholders ended holders nonvoting equity securities give participat allocation targeted nonvoting equity securities ing managers additional incentive achieve continued table contains remuneration equivalent value growth form longterm total shareholder returns nonvoting equity securities allocated psp creating value roche investors management benefits values originally credited member corporate well added value created investors manage executive committee published accordingly remu ment penalised receiving less neration reports roche business report remuneration reportssars money december psp participation programme remuneration distributed ssars psp money disbursementissuance december value granted psp psp psp psp total total total chf chf chf schwan ayyoubi g keller oday p soriot total psp value calculation based corresponding base pay alan hippe roland diggelmann listed table repeated willful failure perform duties since yet roche employees roche corporate reasonably assigned roche executive committee members periods question violation law public regulation commission crime gross negligence willful misconduct employment clawback engaging conduct bringing disgrace disrepute roche addition applicable statutory provisions roches long andor subsidiaries term incentive plans include option partially reclaim dis violation roches directives guidelines relating tributed compensation result special circumstances business conduct clawback according regulations psp programme origi employee voluntarily serves notice termination nally targeted awarded nes shall lapse without employment ssars unvested date termi compensation upon notice termination employment nation employment lapse immediately without compen given reason redundancy disability retire sation ment upon termination employment result serious miscon duct ssars granted outstanding whether vested guidelines security holdings unvested shall lapse immediately without compensation board directors decided ceo according ssars plan rules serious misconduct cec members must acquire shares andor nes equivalent participant may include inter alia two annual base salaries ceo one annual base salary activity leading serious disciplinary action respectively end retain holdings long serve cec type security equivalence ceo shares andor nes x annual base salary members corporate executive committee shares andor nes x annual base salary remuneration report roche business report security holdings solidated financial statements related parties directors andr hoffmann andreas oeri members note financial statements roche holding ltd founders families closely associated significant shareholders addition belong shareholder group pooled voting rights december members board directors end group held shares persons closely associated members issued shares detailed information group cec persons closely associated held shares found finance report note roche group con nes shown table security holdings december close relatives shares nes security holdings others number number numbertype number board directors f b humer ssars see b gehrig hoffmann ubs longshort certificates linked roche bearer shares roche nonvoting equity securities valor isin ch expiry date march p baschera j bell p bulcke w burns ssars see l j r de vink american depository receipts adr rhhby us isin us ch franz julius levinson oeri ubs longshort certificate linked roche bearer shares roche nonvoting equity securities valor isin ch expiry date march p r voser b weder di mauro total corporate executive committee schwan ssars see ayyoubi ssars see r diggelmann ssarsoptions see hippe ssars see g keller shares ssars see oday ssars see total shares shares held shareholders group pooled voting rights listed roche business report remuneration report ssars number ssars held current former members corporate executive committee december total corporate executive committee schwan ayyoubi r diggelmann hippe g keller oday total former corporate executive committee members f b humer none none none none none w burns none none none strike price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports former position options held options shown table issued roche employee stock options option entitles holder purchase one roche nonvoting equity security nes terms multiyear option plan strike price options shown closing price roche nes grant date options shown nontradable onethird options subject vesting period one year onethird vesting period two years onethird vesting period three years unvested options lapse without compensation employment terminated voluntarily reasons retirement vested options must exercised within limited period time franz b humer receive additional ssars franz b humer received ssars member corporate executive committee william burns receive additional ssars william burns received ssars member corporate executive committee remuneration report roche business report independent assurance report corporate governance sustainability committee criteria roche holding ag basel roche roche group internal corporate responsibility reporting guidelines based responsible care health safety performed assurance procedures provide limited environmental protection reporting guidelines published assurance following aspects corporate european chemical industry council cefic responsibility reporting roche sustainability reporting guidelines g published global reporting initiative gri subject matter roche group internal corporate reporting manual data information disclosed corporate responsibility version sustainability reporting economic perfor reporting roche consolidated subsidiaries exclud mance data ing chugai pharmaceutical co ltd business year defined guidelines people donations ended december following aspects sponsorships key figures gathered collated indicated level assurance aggregated internally management reporting processes respect corporate responsibility reporting preparation responsibility methodology people donations sponsorships key figures accuracy completeness corporate responsibility well control environment relation data aggre indicators subject inherent limitations given nature gation key figures limited assurance methods determining calculating estimating key figures including scope co emissions data assurance report therefore read con business travel tables graphs pages nection roches internal guidelines definitions pro selected people key figures disclosed cedures reporting corporate responsibility per pages roche business report formance future orientated data information part limited assurance assurance scope provide assurance consolidated data information roche group statements scope level relation donations sponsorships excluding health care professionals hcps related activities roche corporate governance sustainability commit limited assurance tee responsible preparation presen tation selected subject matter accordance reporting criteria responsibility comprises arrange ment implementation maintenance adequate records internal controls designed support sustain ability reporting processes responsibility form independent conclusion based limited assurance procedures whether anything come attention indicate subject matter stated material respects accordance report ing criteria business year ended december conducted engagement accordance international standard assurance engagements isae issued international auditing assurance standards board roche business report independent assurance reportmain assurance procedures conclusions assurance procedures included following work reference identified subject matter information evaluation application roche group guidelines based work performed nothing come reviewing application roche group internal cor attention causes us believe porate responsibility reporting donations sponsor roche group internal corporate responsibility reporting ships guidelines guidelines based gri g sustainability reporting site visits guidelines well cefic guidelines applied visiting selected sites roches pharma diagnostics material respects accordance reporting cri divisions germany morocco south africa united arab teria emirates singapore usa selection based internal reporting processes collect aggregate quantitative qualitative criteria interviewing personnel people donations sponsorships data func responsible internal corporate responsibility reporting tioning designed provide appropriate data collection sites visited roche basis disclosure material respects accordance group level determine understanding application reporting criteria roche internal corporate responsibility guidelines corporate responsibility information mentioned assessment key figures subject matter disclosed corporate responsibil performing tests sample basis evidence supporting ity reporting roche business report stated selected people donations sponsorships key fig material respects accordance reporting cri ures roche accident rate energy consumption co emis teria sions related energy consumption release halogenated hydrocarbons headcountfte data staff statistics labor practices information contributions philanthropic organi zurich january zations patient organizations health institutions public pol icy bodies concerning completeness accuracy adequacy pricewaterhousecoopers ag consistency review documentation analysis relevant policies basic principles reviewing relevant documentation sample basis including roche group corporate responsibility policies christophe bourgoin stephan hirschi management reporting structures documentation assessment processes data consolidation reviewing appropriateness management ofand reporting processes corporate responsibility key data assessing consolidation process data roche group level independent assurance report roche business report published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identified words believes expects anticipates projects intends seeks fax estimates future imilar expressions discussion among things strategy goals plans intentions various factors may media office cause actual results differ materially future group communications reflected forwardlooking statements contained annual basel switzerland report among others pricing product initiatives competi tel tors legislative regulatory developments economic con fax ditions delay inability obtaining regulatory approvals bring ing products market fluctuations currency exchange rates general financial market conditions uncertainties dis investor relations covery development marketing new products new uses basel switzerland existing products including without limitation negative results clini tel cal trials research projects unexpected side effects pipeline fax marketed products increased government pricing pressures interruptions production loss inability obtain adequate website protection intellectual property rights litigation loss key wwwrochecom executives employees adverse publicity news coverage corporate sustainability committee statement regarding earnings per share growth profit tel forecast interpreted mean roches earnings email corporatesustainabilityrochecom earnings per share subsequent period neces sarily match exceed historical published earnings earnings order publications per share roche tel fax trademarks mentioned enjoy legal protection email baselwebmasterrochecom links third party pages provided convenience express opinion content thirdparty pages next annual general meeting expressly disclaim liability thirdparty information march use roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communications